US.JNJ · Johnson & Johnson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.586637367312035,
        "turnoverUsdM": 2599.7695025523,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.JNJ",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 253.7658,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 2.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 5.2,
      "take_profit_price": 284.4884,
      "target_multiplier": 1.9,
      "technical_strength": 1.93,
      "take_profit_percent": 6.3
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2177972992300024,
    "stopLossPercent": 5.17327473462407,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 80.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 63.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 259.394,
    "ma50": 265.1672,
    "close": 267.61,
    "prevClose": 257.78,
    "avgVolume20": 7813174,
    "volumeRatio": 1.24,
    "changePercent": 3.81
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.056577661086544495,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 0,
      "vol_ratio": 1.2709903165645424,
      "ret_points": 8,
      "vol_points": 4,
      "range_ratio": 1.9589145016467209,
      "volat_points": 4,
      "day_range_pct": 0.03972198870453227,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 80.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 80,
        "contribution": 4
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 20.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67.67,
        "contribution": 20.3
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 63.1,
    "details": [
      "基本面分析總分: 4/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 20.3/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4,
      "資金流": 11.6,
      "市場環境": 10.2,
      "情緒分析": 4,
      "技術信號": 20.3,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.6,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 2599.7695025523,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.JNJ",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.68
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 737.24000235,
                "ma50": 726.3655990799999,
                "name": "QQQ",
                "close": 704.46997,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.7194979,
                "ma50": 768.1665962999998,
                "name": "SPY",
                "close": 763.96002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.586637367312035,
          "atrPoints": 3,
          "cciPoints": 4,
          "vixPoints": 2.4,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143103967,
                "url": "https://finnhub.io/api/news?id=6ba6eb21e59fd6c1286d6cd915cb82479246b421181b0793bf608366b363e3b8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Dow Jones session movers: PG rose 6.01% and JNJ 4.3% to lead 10 gainers, while CAT fell 5.39%, AMZN 4.98% and NVDA 4.37% to lead 8 losers.",
                "category": "company",
                "datetime": 1792696274,
                "headline": "Dow Jones Top Movers Today: PG and JNJ Lead Gainers, CAT and AMZN Lead Losers"
              },
              {
                "id": 143100067,
                "url": "https://finnhub.io/api/news?id=c961cd8dc79da3030f722b8571c7e6f417681b16b6825464c1ab44e73c037770",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals like Merck and AbbVie.",
                "category": "company",
                "datetime": 1792674029,
                "headline": "JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up"
              },
              {
                "id": 143070597,
                "url": "https://finnhub.io/api/news?id=8a2e5bf64d86150682c169c250b064bae6f7bb9fb4b6c47eb5b9318287fa76f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month. It now expects full-year sales of about $101.2 billion at the midpoint, a little higher than its July outlook, and slightly higher adjusted earnings per share too. The company is one of the 10 No-Brainer Stocks to Buy Now. But the quarter behind that […]",
                "category": "company",
                "datetime": 1792603885,
                "headline": "Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?"
              },
              {
                "id": 143067393,
                "url": "https://finnhub.io/api/news?id=2cfdbb5ff2d42448fcadeddd31b638b44cd75475572c5ca6713cdc257ca19876",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1792584005,
                "headline": "Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?"
              },
              {
                "id": 143030193,
                "url": "https://finnhub.io/api/news?id=0deb8ec27691871b9b0708af354692d20f1a9e1a68354e13e21bb6281f156374",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is turning acquired heart technologies into growing sales. Adoption of treatments for hardened arteries supports that strategy, while competition and development spending raise the cost of maintaining its lead. A larger hospital network creates opportunities, but shareholders need ownership to deliver more than a bigger revenue base. Johnson & Johnson (NYSE:JNJ) […]",
                "category": "company",
                "datetime": 1792514312,
                "headline": "Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?"
              },
              {
                "id": 143030195,
                "url": "https://finnhub.io/api/news?id=c9a6adea1a7931c137055ece28d72433e1d6738884fabd3b5db95561c1bd8b58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) introduced the Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S. for calcified coronary lesions. The new catheter is described by the company as a next generation device intended to improve procedural efficiency in coronary interventions. Johnson & Johnson reported long term Phase 3 and extension trial data for TREMFYA and ICOTYDE in Crohn’s disease and plaque psoriasis. The fresh coronary IVL launch and TREMFYA and ICOTYDE data only capture part of the...",
                "category": "company",
                "datetime": 1792512819,
                "headline": "Johnson & Johnson (JNJ) Debuts New Coronary Catheter In The U.S."
              },
              {
                "id": 143025742,
                "url": "https://finnhub.io/api/news?id=081911c80a918d604776b8654fe14e8392cc7b5be205cf5d53e05dd64f63ae50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential.",
                "category": "company",
                "datetime": 1792500360,
                "headline": "Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat"
              },
              {
                "id": 143028849,
                "url": "https://finnhub.io/api/news?id=ad76cdcb6c9d7a852b61ccd0f3f0f3a9c3f8b2c05258a16d1260f4ebd29a3cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The fund bought $35.7 million of Johnson & Johnson and $13.9 million of Shopify as net selling reached $34.3 million on Friday.",
                "category": "company",
                "datetime": 1792494339,
                "headline": "What Capital Group Core Balanced ETF (CGBL) Bought: JNJ Leads on Oct. 16"
              }
            ],
            "raw_source": [
              {
                "id": 143103967,
                "url": "https://finnhub.io/api/news?id=6ba6eb21e59fd6c1286d6cd915cb82479246b421181b0793bf608366b363e3b8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Dow Jones session movers: PG rose 6.01% and JNJ 4.3% to lead 10 gainers, while CAT fell 5.39%, AMZN 4.98% and NVDA 4.37% to lead 8 losers.",
                "category": "company",
                "datetime": 1792696274,
                "headline": "Dow Jones Top Movers Today: PG and JNJ Lead Gainers, CAT and AMZN Lead Losers"
              },
              {
                "id": 143103960,
                "url": "https://finnhub.io/api/news?id=dd0e716c087c296a435bd07e6976db52212f11256849c06f4d99a4595e759e09",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Dow Jones top movers for October 22, 2026: Johnson & Johnson, Salesforce, Home Depot and P&G led gains, while Caterpillar, Nvidia and Amazon led declines.",
                "category": "company",
                "datetime": 1792687276,
                "headline": "Dow Jones Top Movers: Gainers and Losers on October 22, 2026"
              },
              {
                "id": 143103036,
                "url": "https://finnhub.io/api/news?id=4d7a018f3d84e317a422679d6e281251ef3b9cae0203cc0e3d19918750c90cda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Procter & Gamble is surging on a strong earnings beat, but a collapsing gross margin and soaring commodity costs are quietly building pressure beneath the headline numbers. Whether lower-income shoppers keep absorbing higher prices will decide if this rally holds.",
                "category": "company",
                "datetime": 1792684862,
                "headline": "Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up"
              },
              {
                "id": 143102462,
                "url": "https://finnhub.io/api/news?id=42156c80ce82c1bb038822e0c7d5bcbd1cc030ae9bbd5d775138ab153b114746",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson today announced that it has been selected as a Strategic Enterprise by the Hong Kong SAR Government's Office for Attracting Strategic Enterprises (OASES), marking a new chapter in the company's long-standing collaboration with Hong Kong. Johnson & Johnson sees strong alignment with Hong Kong's Five-Year Plan ambition to develop Hong Kong into a Health and Medical Innovation Hub with global influence. Building on more than five decades in the city, Johnson & Johnson will work al",
                "category": "company",
                "datetime": 1792684200,
                "headline": "Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration"
              },
              {
                "id": 143100067,
                "url": "https://finnhub.io/api/news?id=c961cd8dc79da3030f722b8571c7e6f417681b16b6825464c1ab44e73c037770",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals like Merck and AbbVie.",
                "category": "company",
                "datetime": 1792674029,
                "headline": "JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up"
              },
              {
                "id": 143100070,
                "url": "https://finnhub.io/api/news?id=50b76b366ae4508cc62052395656bcd47cf3b798884c6aec97d98627cdfd367b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "She never worked on Wall Street, never hired a financial advisor, and never chased hot stocks, yet her simple portfolio quietly crushed professionals who spent their careers trying to beat the market. The rules she followed are surprisingly within reach for any ordinary investor.",
                "category": "company",
                "datetime": 1792673111,
                "headline": "Kevin O’Leary’s Mother Kept the Same Portfolio for 55 Years and Outperformed Most Hedge Funds"
              },
              {
                "id": 143100048,
                "url": "https://finnhub.io/api/news?id=2664af14cc6088897231f3cbc67e958e4f4b61005f9bf35b5bd4f94ad44457a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792672351,
                "headline": "Was There Any Sign Merck Stock Would Run?"
              },
              {
                "id": 143100069,
                "url": "https://finnhub.io/api/news?id=b869aa3e63fb4030649962b516609a07b4c3977271ec471b7aa4de9c777791ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A 3.3% Social Security bump leaves most retirees short, but five blue-chip dividend payers across four sectors have quietly built the kind of growing income stream that picks up where the government leaves off.",
                "category": "company",
                "datetime": 1792672222,
                "headline": "Social Security Isn’t Enough: 5 Secure Dividend Stocks to Fund Your Retirement"
              },
              {
                "id": 143100049,
                "url": "https://finnhub.io/api/news?id=f51f2cde69be65003b79d129e719322d83ca9adfc7e4b7bee4deb23441f0c884",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792671368,
                "headline": "Is Johnson & Johnson Stock Ready For A MedTech Stall?"
              },
              {
                "id": 143098604,
                "url": "https://finnhub.io/api/news?id=483a5ac1a6d1017d1cd471e104d161ec1269851f07ea46c502c297327a06448d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792669556,
                "headline": "Can Boston Scientific Stock Jump 30%?"
              },
              {
                "id": 143098602,
                "url": "https://finnhub.io/api/news?id=338344d7f9277b25daa856dc2d61b060bfae77c686ed8119f4db3f840f46d3bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "IRVINE, Calif., October 22, 2026--Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment",
                "category": "company",
                "datetime": 1792669500,
                "headline": "Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026"
              },
              {
                "id": 143098603,
                "url": "https://finnhub.io/api/news?id=fdbe53f2595a5de5919ca73be85ac9673fb0d02bf0496e8d5d803d017c5d89b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792667326,
                "headline": "How Has Intuitive Surgical's Story Changed?"
              },
              {
                "id": 143102186,
                "url": "https://finnhub.io/api/news?id=e02aea0905938e8c99013bb3819c14fa895500efa42abcad711a8be5172aeca9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/22/Stock-Market-Trading-Chart-And-Analyzing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Five sectors are higher and six are lower in Thursday’s regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.",
                "category": "company",
                "datetime": 1792666823,
                "headline": "Defensives Lead Sectors In Thursday Trading As Growth Trails"
              },
              {
                "id": 143102000,
                "url": "https://finnhub.io/api/news?id=db97295c1da833b670a9b300b1978ab5844575a24d385e5e4a0173a12d5ce108",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan, South Korea. Both",
                "category": "company",
                "datetime": 1792655270,
                "headline": "Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed"
              },
              {
                "id": 143077026,
                "url": "https://finnhub.io/api/news?id=8f8a087b9a7e3a200ab1b84b9cf25e415216ea987778c64f3c5bfa27f092e2fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792632588,
                "headline": "Can Boston Scientific Stock Bounce Off This Support Again?"
              },
              {
                "id": 143071245,
                "url": "https://finnhub.io/api/news?id=aec8495c2e3c296a8d0ed64027764e3326cca21730a58e6ce7a0425044b98801",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Nasdaq rallies Wednesday as SpaceX stock surges on earnings. Meta Platforms and Tesla post earnings late.",
                "category": "company",
                "datetime": 1792615278,
                "headline": "Stock Market Today: Dow Pops; Nasdaq Charges Higher As SpaceX Soars On Earnings, Tesla Talks"
              },
              {
                "id": 143071288,
                "url": "https://finnhub.io/api/news?id=60fab21e4459df56884c06727fb45337dcfb39de578b8bb76a818cb0b9a2c61f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792614371,
                "headline": "Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?"
              },
              {
                "id": 143069951,
                "url": "https://finnhub.io/api/news?id=18ceb7f9c9bfc0dd34ff0c6c627912be00a08d9b78ab20be862d24f053e77f55",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Nasdaq rallies Wednesday as SpaceX stock surges on earnings. Meta and Tesla are set to report late.",
                "category": "company",
                "datetime": 1792610942,
                "headline": "Stock Market Today: Nasdaq Vaults On SpaceX Report; Software Names Gain (Live Coverage)"
              },
              {
                "id": 143070950,
                "url": "https://finnhub.io/api/news?id=e7e2ceebcdf62fce8337b7b7247e9e07700b6282c2bc5f09ec3fe5809f665395",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson has raised its dividend every single year for 64 years straight, yet a plain S&P 500 index fund still beat it handily over the past decade. Understanding why reveals something surprising about what actually kept long-term shareholders afloat.",
                "category": "company",
                "datetime": 1792606552,
                "headline": "Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?"
              },
              {
                "id": 143070597,
                "url": "https://finnhub.io/api/news?id=8a2e5bf64d86150682c169c250b064bae6f7bb9fb4b6c47eb5b9318287fa76f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month. It now expects full-year sales of about $101.2 billion at the midpoint, a little higher than its July outlook, and slightly higher adjusted earnings per share too. The company is one of the 10 No-Brainer Stocks to Buy Now. But the quarter behind that […]",
                "category": "company",
                "datetime": 1792603885,
                "headline": "Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?"
              },
              {
                "id": 143070600,
                "url": "https://finnhub.io/api/news?id=41f5226f34db5af377548800478d88791c42319afe872a8b5c18c7788b798c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792602406,
                "headline": "What Changed In Amgen's Story?"
              },
              {
                "id": 143070594,
                "url": "https://finnhub.io/api/news?id=f5abb9789bc133fffb098f2944a7386165767acd4b1709ab9cb02f60e4ad6638",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.",
                "category": "company",
                "datetime": 1792601460,
                "headline": "Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock"
              },
              {
                "id": 143070599,
                "url": "https://finnhub.io/api/news?id=3cce3cd2341193d4f670e5042978937e918074723880f9014bec97c161a89089",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Short-term Treasurys now pay more than some beloved dividend stocks, which forces a question retirees rarely had to ask: do decades of consecutive raises still beat a government-backed yield you can lock in today?",
                "category": "company",
                "datetime": 1792599339,
                "headline": "Treasury Yields Are Near 5%. Should Retirees Rethink Dividend Stocks?"
              },
              {
                "id": 143069977,
                "url": "https://finnhub.io/api/news?id=7c39446ebb9278bb2d99569bee16687e10aca18b31406bd86220786f8f187137",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The market has rewarded this biotech for its breakthroughs.",
                "category": "company",
                "datetime": 1792592400,
                "headline": "Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026"
              },
              {
                "id": 143067393,
                "url": "https://finnhub.io/api/news?id=2cfdbb5ff2d42448fcadeddd31b638b44cd75475572c5ca6713cdc257ca19876",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1792584005,
                "headline": "Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?"
              },
              {
                "id": 143061709,
                "url": "https://finnhub.io/api/news?id=fd016f3b6ba6c124f3281acaef8fb917556c7ae5c4332b4518ed516d807ef3b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just posted a 96% profit collapse, yet on the same day raised its full-year guidance and extended a dividend streak most companies only dream about. The reason the headline number is almost completely misleading tells you everything about how to read this stock.",
                "category": "company",
                "datetime": 1792581314,
                "headline": "Johnson & Johnson’s Profit Fell 96% Year-Over-Year. But the Dividend Has Risen for 64 Years in a Row"
              },
              {
                "id": 143099755,
                "url": "https://finnhub.io/api/news?id=72ec799b62eba6edcc9f3e7f04cc4da801cbd0327eecf4bb3f34e9267a270cee",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/21/Stock-Market-Trading-Chart-And-Analyzing.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Five sectors are higher and six are lower in Wednesday’s regular session, with cyclical sectors holding two of the top three positions alongside Technology. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.",
                "category": "company",
                "datetime": 1792580439,
                "headline": "Cyclicals Top Sectors In Wednesday Trading As Defensives Trail"
              },
              {
                "id": 143068518,
                "url": "https://finnhub.io/api/news?id=8ed1a6332aa74c6898213e1ea5e1e797fb821f9a7835d06b641a9aa66f765fb0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206063956/image_2206063956.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "COMPASS Pathways is rated buy, with high risk, based on strong trial design and imminent FDA review for COMP360. Read more on CMPS stock here.",
                "category": "company",
                "datetime": 1792577848,
                "headline": "Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales"
              },
              {
                "id": 143059692,
                "url": "https://finnhub.io/api/news?id=971c8a71f5c3e041b1244361a33a797655e35f20e0a5d3ecba2726e89f699079",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The global medical devices market is projected to grow from $580.79 billion in 2026 to $817.78 billion by 2031, a new report finds, as chronic disease and hospital investment rise, though lengthy approvals and staff shortages weigh; Medtronic, Johnson & Johnson, Abbott and Siemens Healthineers are among 25 companies profiled.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- \"Medical Devices Market: Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. The global medical devices m",
                "category": "company",
                "datetime": 1792573380,
                "headline": "Global Medical Devices Market Size, Share, and Growth Forecast to 2031 | Aging Populations Push the Global Medical Devices Market Toward $818 Billion"
              },
              {
                "id": 143054599,
                "url": "https://finnhub.io/api/news?id=9c7d43a1e17fcc810631ec1ce8d7b370a37dc1954b135d3fcb999bf5daee505e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- \"Life Science Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The global life science market is experiencing rapid expansion, supported by rising pharmaceutical research and development investment, biotechnology innovation, laboratory automation, and growing demand for advanced diagnostics. The market is projected to increase from $109.53 billion in 2025 to $123.41 billion in 2026, representing a compound annual growth rate of 12",
                "category": "company",
                "datetime": 1792570320,
                "headline": "Global Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZeneca"
              },
              {
                "id": 143062081,
                "url": "https://finnhub.io/api/news?id=7e1de78f5891215345dfd6d2e5515ee4c53718422c4da052c229550a4da162b6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355632593/image_1355632593.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Bristol-Myers Squibb yields about 4.3% and trades at 9.1x forward EV/EBIT. Read why BMY stock offers an attractive risk/reward profile.",
                "category": "company",
                "datetime": 1792568710,
                "headline": "Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings"
              },
              {
                "id": 143038856,
                "url": "https://finnhub.io/api/news?id=ec360a4c13d51252fc8575917923e9f0301ecea05f1edc0f73085e8b26ff8f30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Shares of Merck (MRK) returned 76.2% over the past year, compared with 17.4% for the S&P 500. U.S. growth for the company's cancer drug Keytruda is set to slow. Management said on the August 4 call that U.S. Keytruda growth will moderate as the drug reaches peak penetration across several key indications. Barron's also reported on October 7 that a Dutch court barred Merck from selling subcutaneous Keytruda in eight European markets. So how much of what Merck sells is Keytruda.",
                "category": "company",
                "datetime": 1792549234,
                "headline": "What Happens To Merck Stock If Keytruda Sales Stop Growing?"
              },
              {
                "id": 143033042,
                "url": "https://finnhub.io/api/news?id=6120b1166a02a6998e562f4c1221ef443de13ebd507ed850b26fea70024aa16d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors hold Becton Dickinson (BDX) and Boston Scientific (BSX) for newer products that grow faster than the rest of their sales. Becton Dickinson sells everyday hospital supplies such as syringes, with faster-growing lines that include PureWick and biologic drug delivery. Boston Scientific sells cardiology devices such as WATCHMAN. Boston Scientific stock trades at 18.0 times earnings, compared with 55.7 for Becton Dickinson. You gain from that lower price only if the slowdown in WATCHMAN end",
                "category": "company",
                "datetime": 1792537526,
                "headline": "Should Becton Dickinson Stock Holders Look At Boston Scientific Instead?"
              },
              {
                "id": 143032059,
                "url": "https://finnhub.io/api/news?id=526ca852bd13c84f9eed80033a10f76befd97e38898aa8777ca0e9ae4787d595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?",
                "category": "company",
                "datetime": 1792530000,
                "headline": "2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)"
              },
              {
                "id": 143033043,
                "url": "https://finnhub.io/api/news?id=d73331f3abcdeae080388d038ebfb0326e805170e1e0e99170fc4c2c72170b5b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical beat quarterly estimates but disclosed an antitrust settlement and narrowed its procedure-growth forecast.",
                "category": "company",
                "datetime": 1792529160,
                "headline": "Intuitive Surgical Stock Slides Despite Earnings Beat as Company Discloses Settlement"
              },
              {
                "id": 143030196,
                "url": "https://finnhub.io/api/news?id=37654c5ff5faf5a3c52901d051d6fd24f1e786d80816e6eaa999ff9e870243ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Abbott Laboratories (NYSE:ABT) is scheduled to report its earnings on Wednesday, October 21, 2026. The company has a market value of about $181.1 billion. Over the last twelve months it generated $46.6 billion in revenue and $7.3 billion in operating profit, with net income of $5.4 billion.",
                "category": "company",
                "datetime": 1792517940,
                "headline": "Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock"
              },
              {
                "id": 143031681,
                "url": "https://finnhub.io/api/news?id=881cc041f08f15467b0662fcf5a528cc5c286d59149055686324bb6611907161",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Dow Jones top gainers for the Oct. 20, 2026 US session included MMM, UNH, MRK, JNJ, and AMGN, with the article noting their gains and longer-term performance.",
                "category": "company",
                "datetime": 1792514455,
                "headline": "Dow Jones Top Gainers on Oct. 20, 2026: MMM, UNH, MRK Lead Session"
              },
              {
                "id": 143030193,
                "url": "https://finnhub.io/api/news?id=0deb8ec27691871b9b0708af354692d20f1a9e1a68354e13e21bb6281f156374",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is turning acquired heart technologies into growing sales. Adoption of treatments for hardened arteries supports that strategy, while competition and development spending raise the cost of maintaining its lead. A larger hospital network creates opportunities, but shareholders need ownership to deliver more than a bigger revenue base. Johnson & Johnson (NYSE:JNJ) […]",
                "category": "company",
                "datetime": 1792514312,
                "headline": "Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?"
              },
              {
                "id": 143030194,
                "url": "https://finnhub.io/api/news?id=f88e33fd53ac496f0451a2b71c15f4532555e9562f00cf1b095f00bbc79a705e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Rapport licensed the drug from J&J, which is also in the bipolar market with its $14.6bn deal-acquired drug Caplyta.",
                "category": "company",
                "datetime": 1792513891,
                "headline": "Rapport’s novel oral drug posts Phase II bipolar win"
              },
              {
                "id": 143030195,
                "url": "https://finnhub.io/api/news?id=c9a6adea1a7931c137055ece28d72433e1d6738884fabd3b5db95561c1bd8b58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) introduced the Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S. for calcified coronary lesions. The new catheter is described by the company as a next generation device intended to improve procedural efficiency in coronary interventions. Johnson & Johnson reported long term Phase 3 and extension trial data for TREMFYA and ICOTYDE in Crohn’s disease and plaque psoriasis. The fresh coronary IVL launch and TREMFYA and ICOTYDE data only capture part of the...",
                "category": "company",
                "datetime": 1792512819,
                "headline": "Johnson & Johnson (JNJ) Debuts New Coronary Catheter In The U.S."
              },
              {
                "id": 143030197,
                "url": "https://finnhub.io/api/news?id=f7672359de238c9718ee439ab69e7bd868bf6cbda76bfbc91dd1faf721e814a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Alvotech (ALVO) has meaningful stock recovery potential as manufacturing progress boosts confidence",
                "category": "company",
                "datetime": 1792512708,
                "headline": "Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says"
              },
              {
                "id": 143028850,
                "url": "https://finnhub.io/api/news?id=46a47064d2dc2cdee5bbc692ba633bfff95a9e6a3cce5b94bdab3774248fb5f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Dow was popping in early trading as its exposure to non-tech names was paying off.",
                "category": "company",
                "datetime": 1792504738,
                "headline": "Why the Dow Is Leaving the Nasdaq in the Dust"
              },
              {
                "id": 143025742,
                "url": "https://finnhub.io/api/news?id=081911c80a918d604776b8654fe14e8392cc7b5be205cf5d53e05dd64f63ae50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential.",
                "category": "company",
                "datetime": 1792500360,
                "headline": "Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat"
              },
              {
                "id": 143024046,
                "url": "https://finnhub.io/api/news?id=28a59e42f8fa9d7a8a1667ee8926365cb0d42d128f0078f5cbf551ec3ee4bcd6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare and waste management offer long-term demand opportunities beyond AI in 2027, with Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services in focus.",
                "category": "company",
                "datetime": 1792496940,
                "headline": "The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services"
              },
              {
                "id": 143022305,
                "url": "https://finnhub.io/api/news?id=b5d5c4ea62f15cf3379a9ee2becf9b9f7905015aa3949c87ed364628265c86f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Four companies have raised their dividends every single year for decades, but one of them is now paying out nearly every dollar it earns, leaving almost no room for error if business gets worse.",
                "category": "company",
                "datetime": 1792496752,
                "headline": "4 Dividend Kings Retirees Can Buy and Hold Forever: Safe Income for the Next 60 Years"
              },
              {
                "id": 143022306,
                "url": "https://finnhub.io/api/news?id=5d0267e9c9e531a0acee49dbb20dbb564c19e8ed06a9ab60ca8e045010b219d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SANTA CLARA, Calif., October 20, 2026--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.",
                "category": "company",
                "datetime": 1792496700,
                "headline": "Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half"
              },
              {
                "id": 143028849,
                "url": "https://finnhub.io/api/news?id=ad76cdcb6c9d7a852b61ccd0f3f0f3a9c3f8b2c05258a16d1260f4ebd29a3cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The fund bought $35.7 million of Johnson & Johnson and $13.9 million of Shopify as net selling reached $34.3 million on Friday.",
                "category": "company",
                "datetime": 1792494339,
                "headline": "What Capital Group Core Balanced ETF (CGBL) Bought: JNJ Leads on Oct. 16"
              },
              {
                "id": 143022281,
                "url": "https://finnhub.io/api/news?id=50f9b627fa3ce0b22af7021f9aebc3e7da826c78555020e22b24b208e054663b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two drugs, Mounjaro and Zepbound, accounted for $14.9 billion of Eli Lilly's (LLY) $23.0 billion in revenue during fiscal Q2 2026. This leaves Eli Lilly relying on two medicines for most of its sales at a time when the price it gets for them is falling. So why is so much of Eli Lilly's business running through two drugs.",
                "category": "company",
                "datetime": 1792494177,
                "headline": "Is Eli Lilly Stock Too Dependent On Two Drugs?"
              },
              {
                "id": 143029757,
                "url": "https://finnhub.io/api/news?id=8be374748349565bf6e79455346c51db672ba4bbd5436115ca289c0119fc5622",
                "image": "https://image.cnbcfm.com/api/v1/image/108434687-2ED3-MM-E-BLOCK-101926.jpg?v=1792451666&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer weighs in on stocks including: AppLovin, MFA Financial, Vale, Kratos, J&J, Twilio, and Cintas.",
                "category": "company",
                "datetime": 1792438328,
                "headline": "Lightning Round: Twilio is valued correctly, says Jim Cramer"
              },
              {
                "id": 143009428,
                "url": "https://finnhub.io/api/news?id=ecbe5b52205b499c0f97c0666490e6bce8801c6978d22197090dc906176ea7f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Dow Jones index is steady as techs jump on stock market today. Amazon and Nvidia climb while a biotech stock tests a buy point.",
                "category": "company",
                "datetime": 1792429815,
                "headline": "Stock Market Today: Dow Firm, Nasdaq Rallies; Amazon Surges As These Stocks Test Entries (Live Coverage)"
              },
              {
                "id": 143008509,
                "url": "https://finnhub.io/api/news?id=50d1bc3a8e7cdf3b0ac1a17a125d300d6a61758bbaea06444f06dc022823753d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors holding Gilead Sciences (GILD) likely bought into a steady profit engine. The company relies on HIV drugs, led by Biktarvy, to earn money year after year and fund a reliable dividend. Gilead spent the first half of 2026 acquiring other businesses, including Arcellx and Tubulis, before reporting its fiscal second quarter on August 4, 2026. What did those deals do to the profit you were counting on.",
                "category": "company",
                "datetime": 1792424621,
                "headline": "What Has Changed About Owning Gilead Stock?"
              },
              {
                "id": 143008508,
                "url": "https://finnhub.io/api/news?id=8b5afed948d5232e05286adee6a0e873ad7d7b85f7c41fb5aaa215844bda614f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) stands out in the healthcare world for a reason. Its massive scale, strong research teams, and deep relationships with hospitals and medical professionals give it an edge that’s tough for competitors to match. The company’s Innovative Medicine branch creates treatments for tough diseases, while its MedTech division provides equipment for surgeries, […]",
                "category": "company",
                "datetime": 1792418738,
                "headline": "Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up?"
              },
              {
                "id": 143006653,
                "url": "https://finnhub.io/api/news?id=386994ad1b915aacd0f3e2946fda99a53750ec2c6ca543aabe7073b639e6373d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A CD and a dividend stock can both pay you income in retirement, but they make very different promises, and breaking one of them could cost you far more than a lower yield.",
                "category": "company",
                "datetime": 1792417558,
                "headline": "Ds vs. Dividend Stocks: One Protects Your Principal, the Other Could Grow Your Income"
              },
              {
                "id": 143006654,
                "url": "https://finnhub.io/api/news?id=d4e50af581b1603134cb9ed60f289ba8872d31548eb89e54214476c5280afdf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A risk-free bond now pays enough to make most dividend stocks look pointless, but three companies have raised their payouts for over 50 straight years and carry betas low enough to sleep through a rate spike.",
                "category": "company",
                "datetime": 1792417526,
                "headline": "3 Dividend Kings to Buy Now for Protection Against Rising Rates"
              },
              {
                "id": 143008510,
                "url": "https://finnhub.io/api/news?id=f4eaaedff97b4972d50dc0563b022d88089a838a0b6e9ab48df93d50dbe497ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SYK's $400 million investment in CMR Surgical marks its entry into soft-tissue robotics, expanding its surgical portfolio with Versius technology.",
                "category": "company",
                "datetime": 1792415700,
                "headline": "Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal"
              },
              {
                "id": 143006655,
                "url": "https://finnhub.io/api/news?id=6fc55294eb2b77d1bff625e46a2a4e0239cef49babb369b6437fea14c62c039c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) stock is under fresh scrutiny after European regulators recommended expanding TALVEY’s use in relapsed or refractory multiple myeloma, adding another data backed oncology asset to the healthcare giant’s pipeline. For investors tracking the bigger picture, Johnson & Johnson’s recent drug updates, dividend affirmation and third quarter earnings all land against a share price of US$255.56, with a year to date share price return of 23.25% and a 1 year total shareholder...",
                "category": "company",
                "datetime": 1792415366,
                "headline": "Is Johnson & Johnson (JNJ) Undervalued Following Its Latest Oncology Update?"
              },
              {
                "id": 143006605,
                "url": "https://finnhub.io/api/news?id=d8336ff84d088f1fee01e07ce68f8bcfd97ec3f72a7cc63f58f1d6840e973601",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors are paying a premium for Johnson & Johnson (JNJ) stock. It trades at 29.2 times earnings, compared to 22.9 for the S&P 500. Shareholders paying that premium need to understand exactly what they are buying, and the priorities at the company have changed. A year ago, during the fiscal Q3 2025 call, executives emphasized how the business would maintain growth despite the loss of exclusivity for STELARA, which is the point when rivals can sell copies of a drug. The corporate focus has shif",
                "category": "company",
                "datetime": 1792414556,
                "headline": "Has Johnson & Johnson Stock Become A Different Bet?"
              },
              {
                "id": 143006658,
                "url": "https://finnhub.io/api/news?id=128f392596d085f3a087a2d4ba623a478b80c0f19e3bbeaab0568482cbae6a3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.",
                "category": "company",
                "datetime": 1792411200,
                "headline": "AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results"
              },
              {
                "id": 143006657,
                "url": "https://finnhub.io/api/news?id=19198ddac980d4a73b630c0fbfec6fdd055f7744e7ee1aa9d65a0ce9999473fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn's disease (CD).1 The findings build on the previously reported Week 24 results and further support the use of TREMFYA in one of the most difficult-to-treat manifestations of CD 2. The late-breaking findings are being presented at the 2026 United European Gastroenterology Week (UEG Week).",
                "category": "company",
                "datetime": 1792411200,
                "headline": "Johnson & Johnson   announces   new data   showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula   remission through 48 weeks in Crohn's disease with perianal fistula"
              },
              {
                "id": 143022308,
                "url": "https://finnhub.io/api/news?id=c4a58a72ce76dc86996fa8a13febc9ed457febae477028581aa7529a5e560d62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.",
                "category": "company",
                "datetime": 1792409400,
                "headline": "What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs"
              },
              {
                "id": 143005743,
                "url": "https://finnhub.io/api/news?id=f5a6cd78c15e0515c9af271b1393a8bd926823a0d1d656706a815f9318c4b707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is what the numbers actually say about whether this healthcare giant earns its premium valuation.",
                "category": "company",
                "datetime": 1792408521,
                "headline": "Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead"
              },
              {
                "id": 143007837,
                "url": "https://finnhub.io/api/news?id=70c02f0407992eddc531adc244fe207d391951092780e4ef5e19e54e1eea4245",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose groupThese findings build on the Phase",
                "category": "company",
                "datetime": 1792397330,
                "headline": "Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease"
              },
              {
                "id": 142961932,
                "url": "https://finnhub.io/api/news?id=ef513cc72722e019f46a44d41cce85ab89b5ebf1194606b42bc3f4624d371c29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Looking beyond near-term headwinds paints a fairly bright picture of Johnson & Johnson’s outlook.",
                "category": "company",
                "datetime": 1792249921,
                "headline": "Should You Invest in This Dividend King on the Dip?"
              },
              {
                "id": 142961958,
                "url": "https://finnhub.io/api/news?id=e87fb12b8e9c1708a4ae403c0de93b2c8c68f0b22f492b70de64be9dd0a3313f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Raising dividends through two recessions takes more than a good brand name. Three companies with streaks stretching back decades show exactly what separates a payout that survives a crisis from one that quietly disappears.",
                "category": "company",
                "datetime": 1792245618,
                "headline": "Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage"
              },
              {
                "id": 142960211,
                "url": "https://finnhub.io/api/news?id=3cd6b334dacd22b1da54c95de7946c5985810e696ccdc4478ddbe6dac4398fb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee deal and lingering debt load could mean for the payout's future.",
                "category": "company",
                "datetime": 1792238420,
                "headline": "AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?"
              },
              {
                "id": 142960010,
                "url": "https://finnhub.io/api/news?id=c3bb8900b1fbc403ac7002346e83167ebd87153a0b81791527a07965c14cc25b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "These companies generate resilient revenues, which help make their stocks less volatile during market downturns.",
                "category": "company",
                "datetime": 1792236000,
                "headline": "When the Stock Market Gets Dangerous, These 6 Investments Have a History of Holding Up"
              },
              {
                "id": 142986233,
                "url": "https://finnhub.io/api/news?id=568e63e4c6d4bd104d2b5f3477ca384696dd07bd8f515a2913346504239748cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Tech stocks fell on inflation fears and AI infrastructure concerns while the Dow rose, as MarketBeat analysts review earnings outlooks, sector rotation, and stock picks from the week's top stories.",
                "category": "company",
                "datetime": 1792234800,
                "headline": "MarketBeat Week in Review – 10/12 - 10/16"
              },
              {
                "id": 142959986,
                "url": "https://finnhub.io/api/news?id=98dbf11664a7e95ce7d8b907a772c2066444e9ac53c83fc391c4f9a1d650e0c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests.",
                "category": "company",
                "datetime": 1792233300,
                "headline": "Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy."
              },
              {
                "id": 142957851,
                "url": "https://finnhub.io/api/news?id=7fbbc87921f5eb6aebe1a84de39e7ad8c2e918ec67c718d7d159b99c51415cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs, Zepbound and Mounjaro, accounted for most of the company's sales. How early did those two drugs show up in what Lilly said and filed.",
                "category": "company",
                "datetime": 1792205822,
                "headline": "What Was Eli Lilly Telling You Before Its Stock Ran?"
              },
              {
                "id": 142956490,
                "url": "https://finnhub.io/api/news?id=32f01879d65f189bc0378db39879d27c143e76f50df0c70eda8c6055ddf5fef4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of pressure often pushes investors toward higher risk, higher potential areas like biotechnology. Volatile times can create pricing gaps where careful stock picking matters more than ever. This article highlights three biotech stocks with comparatively solid finances that could appeal if you are hunting for calculated exposure to breakthrough science. The stocks covered next are...",
                "category": "company",
                "datetime": 1792199621,
                "headline": "3 Great Biotech Stocks To Watch In October 2026"
              },
              {
                "id": 142956254,
                "url": "https://finnhub.io/api/news?id=0936d03373bb17e263e876ceb2e2b2190733d790f2fa4fc4d26706b91436d608",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.",
                "category": "company",
                "datetime": 1792199402,
                "headline": "Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142955409,
                "url": "https://finnhub.io/api/news?id=ddb56e3c9661675f49062aebfa86d5d29be9a5e9841df1481875ad51a4717ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.",
                "category": "company",
                "datetime": 1792198389,
                "headline": "When Amgen's Forecast And Chart Say The Same Thing, Pay Attention"
              },
              {
                "id": 142954216,
                "url": "https://finnhub.io/api/news?id=4ceb14cf168e6a03b7c306392042043ca662a3e864ad75e2c2967d3eb042758f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal 2025 revenue. Yet another segment of the HIV business is growing at a much faster pace, and it targets people who do not currently carry the virus. Gilead expects a regulatory decision regarding a new option in this category in early 2027. So what is that business, and how much is it selling today.",
                "category": "company",
                "datetime": 1792197478,
                "headline": "Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?"
              },
              {
                "id": 142953213,
                "url": "https://finnhub.io/api/news?id=e0d5644bdb1a894b876cd8a527913e2c730f1125e7d0685ae819033f70376096",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.",
                "category": "company",
                "datetime": 1792196033,
                "headline": "Is Amgen Stock Increasing Your Market Risk?"
              },
              {
                "id": 142950832,
                "url": "https://finnhub.io/api/news?id=4db4de74806b0e5104f5f77118d9ce95cdc886f0252f7f43af6b42e9db72fde1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels heading into its Q3 earnings release on October 20.",
                "category": "company",
                "datetime": 1792180320,
                "headline": "Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside"
              },
              {
                "id": 142950069,
                "url": "https://finnhub.io/api/news?id=4a4cff3e5e3e5b1618597e7c00b303bf722f44e0e90c942709ab4988337b671d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.",
                "category": "company",
                "datetime": 1792174479,
                "headline": "Johnson & Johnson: 3 Key Takeaways for Long-Term Investors"
              },
              {
                "id": 142945597,
                "url": "https://finnhub.io/api/news?id=417b8239ccec864a5ac691231b8f2019ed48186bfc07b59a2d383eda26bb1236",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized. Jim Cramer and others are pointing to a handful of quiet winners that keep paying dividends no matter what chip stocks do.",
                "category": "company",
                "datetime": 1792156812,
                "headline": "The Stocks That Will Get Investors Home Safe When Tech Cracks"
              },
              {
                "id": 142960972,
                "url": "https://finnhub.io/api/news?id=29037aa047eedc5b98872c652d439977c9ae88de2776d706c687b411e7103793",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $275 to $287.",
                "category": "company",
                "datetime": 1792152464,
                "headline": "Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287"
              },
              {
                "id": 142947639,
                "url": "https://finnhub.io/api/news?id=2849d0ac5038a97fc9e2dc41b2da58d5dbeae2e3c1c739eaab8a464d56a914f3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/16/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.",
                "category": "company",
                "datetime": 1792148420,
                "headline": "9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead"
              },
              {
                "id": 142942274,
                "url": "https://finnhub.io/api/news?id=5936503ca7e7b095040b9d828adc3e683b6b22cfd534bf0c4eb17952e484aabf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson reported third quarter 2026 sales of US$25,399 million and net income of US$210 million, raised its full year outlook, and affirmed a US$1.34 per share fourth quarter dividend payable in December 2026. Strong demand for TREMFYA, early momentum for ICOTYDE, and continued focus on oncology helped offset weaker MedTech performance and international pricing pressure for Johnson & Johnson. We will look at how Johnson & Johnson's raised 2026 guidance, despite softer MedTech...",
                "category": "company",
                "datetime": 1792145733,
                "headline": "Does Raised 2026 Outlook Change The Bull Case For Johnson & Johnson (JNJ)?"
              },
              {
                "id": 142945363,
                "url": "https://finnhub.io/api/news?id=ac87e540373fd353d34b65938382948ae27936b8bda1c6216dae9aed4a6cd821",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma",
                "category": "company",
                "datetime": 1792141077,
                "headline": "Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma"
              },
              {
                "id": 142922978,
                "url": "https://finnhub.io/api/news?id=72238688ce9bdd704d54016de9e4138a1127b0155c79e11b90d17d1c81226f29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Raised guidance is always a welcome development for investors, reflecting improving business trends and management confidence in the outlook.",
                "category": "company",
                "datetime": 1792099380,
                "headline": "3 Companies Raising Guidance This Earnings Season"
              },
              {
                "id": 142922277,
                "url": "https://finnhub.io/api/news?id=98c466238a1dcdfedbdbfd830252eb68f2e76c05efe213aa068bd61a3c79061f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors considering Medtronic (MDT) stock face an immediate concern: the shares returned 1.9% over the past year, trailing the 17.3% gain for the S&P 500. Yet Medtronic raised its outlook for the year in September, following higher fiscal first-quarter profit and sales. The company is also splitting off MiniMed Group, meaning the business you buy today is changing. So how much faster is Medtronic actually growing.",
                "category": "company",
                "datetime": 1792098071,
                "headline": "Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up?"
              },
              {
                "id": 142922269,
                "url": "https://finnhub.io/api/news?id=c7865f7724923f82ec5f2ffee87e7389c60a2dc5ec98a0c9ffd0eb37e2d969ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.",
                "category": "company",
                "datetime": 1792093589,
                "headline": "How Has Merck's Story Changed?"
              },
              {
                "id": 142921392,
                "url": "https://finnhub.io/api/news?id=2c78bcaaa7a43c6a46f54c48bf514d18ebf0401dc2599a79c95b2a6dd89ac00c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors in Boston Scientific (BSX) hold stakes in a medical device maker that grew revenue 13.5% over the twelve months to June 2026. Yet the shares have lost 54.7% over the past year, trailing a 17.3% gain for the S&P 500. In August, a cyberattack disrupted the company's manufacturing and order shipments. So has the risk in holding Boston Scientific shares gone up or down over the past year.",
                "category": "company",
                "datetime": 1792091887,
                "headline": "Is Boston Scientific Stock Riskier Than It Was A Year Ago?"
              },
              {
                "id": 142921152,
                "url": "https://finnhub.io/api/news?id=545db4733871e90a22820d700146d007479454afeb887e72faa3fb5e27048e68",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1792091412,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 142920367,
                "url": "https://finnhub.io/api/news?id=95f88b38811524b9e980e99d804fd5961531f8d4695a052d4874396c8d9cbfac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it. These five blue chips clear that bar, and one has done it every single year for seven decades.",
                "category": "company",
                "datetime": 1792086323,
                "headline": "Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Also Reward Patience"
              },
              {
                "id": 142920368,
                "url": "https://finnhub.io/api/news?id=b0ea7dc4bc4c0d63d35e5cb69f207301a8dca1feb56bceb48e6c0f68d9f4af98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.",
                "category": "company",
                "datetime": 1792080300,
                "headline": "XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?"
              },
              {
                "id": 142920126,
                "url": "https://finnhub.io/api/news?id=80f575833dd40e4a58391d1722ae1a5b099c425c5863a9e1e2c10ace1c8f0bad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2293185243/image_2293185243.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "AngioDynamics, Inc. stock analysis: AlphaVac, Auryon, NanoKnife growth vs execution risk and margin swings. Click for this updated look at ANGO prospects.",
                "category": "company",
                "datetime": 1792070828,
                "headline": "AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist"
              },
              {
                "id": 142915328,
                "url": "https://finnhub.io/api/news?id=b3a8c83dcbe2957ee2b7ef5bda75d1c593820e341cd92a0184bdff2f60f5c80b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors paying that premium appear to be counting on more growth. The company raised its 2026 guidance on October 13, and Chief Executive Joaquin Duato pointed to one new product as one of its most transformative MedTech innovations. So which product is it.",
                "category": "company",
                "datetime": 1792069769,
                "headline": "Where Could Johnson & Johnson's Next Growth Come From?"
              },
              {
                "id": 142919904,
                "url": "https://finnhub.io/api/news?id=10e4343537faceb2924284039eb4ed431ab6462c2e4f47042d7cba8b0e03e2a0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186944301/image_2186944301.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Alto Neuroscience, Inc. pivots to ALTO-207 for treatment-resistant depression; learn risks, catalysts, dilution, and outlook. Click for this ANRO stock update.",
                "category": "company",
                "datetime": 1792069651,
                "headline": "Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold"
              },
              {
                "id": 142945364,
                "url": "https://finnhub.io/api/news?id=843ef2a5788b51bc5c79a00ac8826934b3e3d61bd73dbd97675cd1d6c7ee5065",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $294 to $292.",
                "category": "company",
                "datetime": 1792068753,
                "headline": "Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292"
              },
              {
                "id": 142920033,
                "url": "https://finnhub.io/api/news?id=0bbe7bf9490a7e542414e40c7ebce1ded251c65a0a2b90287b1349b2909b84e0",
                "image": "https://image.cnbcfm.com/api/v1/image/108414323-17920727101792072707-49016299898-1080pnbcnews.jpg?v=1792072709&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Jim Cramer's gives his insight regarding this healthcare giant.",
                "category": "company",
                "datetime": 1792058402,
                "headline": "Cramer’s Stop Trading: Johnson & Johnson"
              },
              {
                "id": 142894617,
                "url": "https://finnhub.io/api/news?id=a15dbaf0ec5913d78ad6dd47f8be522dd0a51efa769661f4a206c2f7086f658e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% on September 30 after a federal judge ruled that Yutrepia, Liquidia's inhaled lung drug, infringes a United Therapeutics patent. Liquidia subsequently settled all pending litigation with United Therapeutics on October 13, stating that Yutrepia will remain available to patients with PAH without disruption. If the wider market sells off from here, how mu",
                "category": "company",
                "datetime": 1792028830,
                "headline": "How Much Downside Is Left In Liquidia Stock?"
              },
              {
                "id": 142888398,
                "url": "https://finnhub.io/api/news?id=ef7c7029bef1f6c640c65a25788aafde6dcff4633ad4476372e4ff68562445ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Boston Scientific (BSX) stock currently trades at 17.2 times earnings. This compares to an average multiple of 55.9 over the last twelve quarter-ends, excluding readings above a hundred. Investors evaluating the stock must look ahead to model potential returns. So what might a share bought at $43.31 be worth three years from now.",
                "category": "company",
                "datetime": 1792011329,
                "headline": "What Could BSX Stock Be Worth In Three Years?"
              },
              {
                "id": 142887223,
                "url": "https://finnhub.io/api/news?id=0da62e5b5741f2c815f6c9d71ebb7308149769088a6488e233b3825b4510e5a1",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1792005015,
                "headline": "Discover which dow jones stocks are making waves on Wednesday."
              },
              {
                "id": 142888397,
                "url": "https://finnhub.io/api/news?id=480d3682d7e458c274910231e3e67e274873fe877a2a7d687179a782e8bae3e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharma company is on track to reach $100 billion in recorded revenue despite “temporary” headwinds in its medtech segment, executives said.",
                "category": "company",
                "datetime": 1792003439,
                "headline": "Johnson & Johnson CFO taps internal investment for medtech growth"
              },
              {
                "id": 142888330,
                "url": "https://finnhub.io/api/news?id=7cc8cebe36a96844c7171a8bfe00ab71c7475d484ecd225cd55276f0950d1c5c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/512117406/image_512117406.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "JNJ Q3 2026 earnings look strong, but deeper analysis shows declining shareholder earnings. Click for more on JNJ stock.",
                "category": "company",
                "datetime": 1792000489,
                "headline": "Johnson & Johnson: Stop Paying A Premium For Disappointment - Strong Sell"
              },
              {
                "id": 142917428,
                "url": "https://finnhub.io/api/news?id=64f5eb3be43b427b92e2e4baee6714fee403bbba89253e664e3d172a69f98558",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Leerink Partners  analyst David Risinger   maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $276 to $272.",
                "category": "company",
                "datetime": 1791996262,
                "headline": "Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $272"
              },
              {
                "id": 142885917,
                "url": "https://finnhub.io/api/news?id=0e4a0f899d47f594522938c4a59506903cbb4ca15d3de14660f12bd82568ba62",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the top performers within the dow jones index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1791996018,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 142887363,
                "url": "https://finnhub.io/api/news?id=692dfbf5bf9e98d3c7d3767a76b2a835e8b5e92ca04443e9ab187dfd9d5fc783",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2298237779/image_2298237779.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "GSK plc stock update: oncology pipeline momentum (Mo‑Rez phase 1), Cabenuva HIV data, Q2 results and 2026 phase 3 plans—click for this GSK update.",
                "category": "company",
                "datetime": 1791993350,
                "headline": "GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion"
              },
              {
                "id": 142886457,
                "url": "https://finnhub.io/api/news?id=495209183eea6d7318d1d4db2134daf72888cf50b52194a8d8bf4877687ca229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.",
                "category": "company",
                "datetime": 1791990540,
                "headline": "Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?"
              },
              {
                "id": 142885169,
                "url": "https://finnhub.io/api/news?id=e9792bb6df51e0e1ba93cc592e215d880009c8dda3e65f0fd008afab16ce69af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's (JNJ) review of its enterprise business on Dec. 8 is expected to sharpen the com",
                "category": "company",
                "datetime": 1791989853,
                "headline": "Johnson & Johnson's Enterprise Review Expected to Sharpen Outlook, Morgan Stanley Says"
              },
              {
                "id": 142885170,
                "url": "https://finnhub.io/api/news?id=33209536bf668dda214c0bff5ebf24b0ce8deee3c8f1122073ac32cda9cc5d86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's shares fell 5.8% despite an earnings beat and raised guidance, as MedTech weakness, drug sales shortfalls and acquisition costs weighed on results.",
                "category": "company",
                "datetime": 1791986220,
                "headline": "Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?"
              },
              {
                "id": 142886345,
                "url": "https://finnhub.io/api/news?id=2eb132da1e00b89ebe033b6e08337f524981d6412c48c58cd5cbcdcc18f6afed",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296348532/image_1296348532.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Want to retire on income? Learn how a dividend portfolio using preferred shares and baby bonds can boost yield on cost and preserve principal.",
                "category": "company",
                "datetime": 1791986068,
                "headline": "How To Retire: Hope For 95, Prepare For 105"
              },
              {
                "id": 142882638,
                "url": "https://finnhub.io/api/news?id=931b36566ec23c66fd80f3da2316a383e543e0e0ac72e8c91f17629a91edad8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most investors chase the highest yield they can find, but that single decision quietly destroys the income they worked to build. A three-bucket approach solves a tension most dividend strategies ignore entirely.",
                "category": "company",
                "datetime": 1791985802,
                "headline": "The 3-Bucket Income System Making $13,000/Month in Pure Dividends"
              },
              {
                "id": 142882639,
                "url": "https://finnhub.io/api/news?id=c3476b369a8d0c3a88271bd66c4dc069d1b08afda1b7dd2e2b7f9b4aa10f4e18",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Key Stats for Johnson and Johnson StockPrice change for Johnson and Johnson stock in the last 6 months: 4%$JNJ Stock Price as of Oct. 13: $24952-Week High: $281$JNJ Stock Price Target: $280What Happened?Johnson & Johnson (JNJ:NYSE) beat third-quarter estimates on Tuesday, but the stock still fell because sales in its medical devices business, MedTech, were weak.",
                "category": "company",
                "datetime": 1791985733,
                "headline": "Johnson and Johnson Stock Plunges 6% As Medical Device Sales Miss Wall Street Forecasts"
              },
              {
                "id": 142917429,
                "url": "https://finnhub.io/api/news?id=0f3e79f4cd1dacf6485299c4139f3ef056b6f4c065cf8ad0b3e0abcab525f7cd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Johnson--Johnson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson posted upbeat Q3 results; analysts stayed bullish, though RBC cut its target and noted mixed product and MedTech trends.",
                "category": "company",
                "datetime": 1791985555,
                "headline": "Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts"
              },
              {
                "id": 142885171,
                "url": "https://finnhub.io/api/news?id=c9b08647716d071ec6fe0b839a128a131ee7c33e8c360c3b991b6ae616ec8402",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.",
                "category": "company",
                "datetime": 1791984660,
                "headline": "J&J earnings set ‘negative tone’; Shkreli vs. the FTC"
              },
              {
                "id": 142882640,
                "url": "https://finnhub.io/api/news?id=ea60693e5047bdf098e1ba9e7d7c0513130590456234d1e7c46588af6ee81a73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Kevin O'Leary's retirement playbook starts with a warning that catches most people off guard, and it has nothing to do with stocks or bonds. His three rules draw a hard line between emotional decisions and the money you cannot afford to lose.",
                "category": "company",
                "datetime": 1791984635,
                "headline": "Kevin O’Leary Warns: ‘Do Not Invest in Your Brother’s Restaurant.’ Here Are His 3 Rules for Retirement Money"
              },
              {
                "id": 142917430,
                "url": "https://finnhub.io/api/news?id=0ea45205af675539a5b4204e073bfb06d19ce71993b4e574e57d46691cc84072",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson beat Q3 estimates and raised full-year guidance; sales rose 5.9%, EPS fell 7.5%. Analysts trimmed price targets.",
                "category": "company",
                "datetime": 1791983161,
                "headline": "These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results"
              },
              {
                "id": 142882629,
                "url": "https://finnhub.io/api/news?id=e7ee454d06681d6eed59a914146d59e967214b8f3d686043bbcc75da682651e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.",
                "category": "company",
                "datetime": 1791980295,
                "headline": "The Open Question Under Johnson & Johnson Stock's Price"
              },
              {
                "id": 142881685,
                "url": "https://finnhub.io/api/news?id=e763de698418aec47744b120467a490b683d9828a9163494ff75c2b553ce7a01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.",
                "category": "company",
                "datetime": 1791976559,
                "headline": "J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says"
              },
              {
                "id": 142881695,
                "url": "https://finnhub.io/api/news?id=7fea1d49ce468ac5cda1986cdec52c42bb30275066096747e2bcadca75f062b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something bigger, and the math behind their payouts tells the story.",
                "category": "company",
                "datetime": 1791976502,
                "headline": "Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying"
              },
              {
                "id": 142882642,
                "url": "https://finnhub.io/api/news?id=6ba1991a6e59a09f4fc937ac294bea75e153edef79481fff684bcd96b3600726",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution clouds the outlook.",
                "category": "company",
                "datetime": 1791976320,
                "headline": "JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges"
              },
              {
                "id": 142917431,
                "url": "https://finnhub.io/api/news?id=ee15590418bdd9d6526268a79ab42c8299b6aa1410f37e5ceaebdb937fc13773",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $282 to $275.",
                "category": "company",
                "datetime": 1791975563,
                "headline": "Wells Fargo Maintains Overweight on Johnson & Johnson, Lowers Price Target to $275"
              },
              {
                "id": 142879285,
                "url": "https://finnhub.io/api/news?id=8cb73376d702b0ea1d04a80d3f05facddbcb644066296993edbdbf296a1d3a20",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_19_d704b1b5a8.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "JPMorgan, Goldman, Citi and Wells Fargo earned nearly $32 billion but trading desks sent mixed signals. Bumble jumped 57% on a buyout; ASML beat this morning.",
                "category": "company",
                "datetime": 1791975103,
                "headline": "Stock Market Today: Big Banks Earn Billions, Bumble Soars on Buyout"
              },
              {
                "id": 142877597,
                "url": "https://finnhub.io/api/news?id=ee485ffa353f95fe16ec1c801f3480957cdbc1614c6525f24ae2c64f26aed4b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Gabelli Funds Portfolio Manager Justin Bergner and NYSE Senior Market Strategist Michael Reinking break down how the AI boom, rising interest rates, and geopolitical tensions are fundamentally reshaping the stock market.",
                "category": "company",
                "datetime": 1791972000,
                "headline": "What the interest rate danger zone means for your money"
              },
              {
                "id": 142884220,
                "url": "https://finnhub.io/api/news?id=3f42b434ab9d8d8a12eabbb7ffd6ba996874ec930d583380747a0d81c180263c",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "RBC Capital  analyst Trung Huynh   maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target from $290 to $280.",
                "category": "company",
                "datetime": 1791970532,
                "headline": "RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280"
              },
              {
                "id": 142884221,
                "url": "https://finnhub.io/api/news?id=cbe396f6ae8bfc01cfcd7c9a26a47f18b707e66b4514e3b0740e7e5986047b5c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/New-Brunswick--New-Jersey--November-1--2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson found support near $246 after an earnings drop, with buy orders potentially signaling a bottom and rally.",
                "category": "company",
                "datetime": 1791969683,
                "headline": "Stock of the Day: Is this the Bottom for Johnson & Johnson?"
              },
              {
                "id": 142874877,
                "url": "https://finnhub.io/api/news?id=cf4c16068a42ac1b12f05cddda29a48c9b683bada8e254d4c991d323ca859a13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.",
                "category": "company",
                "datetime": 1791966260,
                "headline": "SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals"
              },
              {
                "id": 142869843,
                "url": "https://finnhub.io/api/news?id=310ef25895cc39730bc02d53261c2e29cfcc1b7eb4f0498474d0e9c56b8614e8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196086989/image_1196086989.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Visible Alpha consensus expects the Dow Jones Industrial Average to deliver an 18.7% weighted price return in the medium term. Read more here.",
                "category": "company",
                "datetime": 1791948000,
                "headline": "Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps"
              },
              {
                "id": 142863633,
                "url": "https://finnhub.io/api/news?id=665574b8058cde2b5067dd46833eaa55061274b0b8fc99598cde8e7ec9e4d68c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The J&J selloff shows how medtech weakness can outweigh pharma strength, and what it means for healthcare stocks.",
                "category": "company",
                "datetime": 1791940069,
                "headline": "J&J Selloff Exposes Medtech Strain: Is Pharma Carrying Healthcare Stocks?"
              },
              {
                "id": 142860920,
                "url": "https://finnhub.io/api/news?id=f199c477da42859248c6da8b21bc06ff2e39ac914c7f6a9c9bc8b500497b3614",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion.",
                "category": "company",
                "datetime": 1791935965,
                "headline": "J&J (JNJ) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 142859279,
                "url": "https://finnhub.io/api/news?id=14c8e707d92d8e0e8be0ddc12789e4925bf042dc3bab105ffcdb4208cca4d447",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors were unimpressed with solid results from big banks. Wall Street is in a pessimistic mood. That may not be a bad thing.",
                "category": "company",
                "datetime": 1791935700,
                "headline": "Review & Preview: Not a Bang but a Whimper"
              },
              {
                "id": 142856069,
                "url": "https://finnhub.io/api/news?id=19ddbf443d05e538002ed8fb8a4b92ac9ed26efb14a4416a1787066e2d586672",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what",
                "category": "company",
                "datetime": 1791935331,
                "headline": "Is Amgen Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142858871,
                "url": "https://finnhub.io/api/news?id=0c9ae6fa2deb4cc775d70d7ffbc879a07bae59858cff028b7b667555d524eb46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare giants UnitedHealth Group and Johnson & Johnson reported Q3 results on Tuesday, with both raising their full-year earnings outlooks but delivering contrasting reports.",
                "category": "company",
                "datetime": 1791933000,
                "headline": "UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings?"
              },
              {
                "id": 142854421,
                "url": "https://finnhub.io/api/news?id=4b783e926aa9763e8bd7657597000af52916710820b5b65f891b0fb24b4be8de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most people reach for the 4% rule when they picture retiring at 56 on nearly $6,000 a month, but that rule answers a completely different question than a dividend portfolio does, and the gap between the two changes everything about which accounts you use and whether you can even touch the money.",
                "category": "company",
                "datetime": 1791926560,
                "headline": "Retiring at 56 on $5,950 a Month for Life: The Portfolio Size Most People Guess Wrong"
              },
              {
                "id": 142882268,
                "url": "https://finnhub.io/api/news?id=56f323b779743a1311b917fd505da312e5250bede4e155261768b4d5ddf01d59",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "BAC, JNJ, FUN, C, AMAT were among the stocks seen trending among investors on Tuesday, Oct. 13, 2026.",
                "category": "company",
                "datetime": 1791926495,
                "headline": "Bank of America, Johnson & Johnson, Six Flags Entertainment, Citigroup and Applied Materials: Why These 5 Stocks Are on Investors' Radars Today"
              },
              {
                "id": 142854375,
                "url": "https://finnhub.io/api/news?id=9e660432745a6b3048656bec17f9952d8958314c5e84bae81f091f418a70be15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare and semiconductor stocks led declines as investors digested mixed corporate results and competitive pressures, today, Oct. 13, 2026.",
                "category": "company",
                "datetime": 1791926061,
                "headline": "Stock Market Today, Oct. 13: Markets Edge Lower as Earnings Season Kicks Off"
              },
              {
                "id": 142855339,
                "url": "https://finnhub.io/api/news?id=16cb9c691d140bfee1b035c503637a22f0aafe61a33af6cfb01c1c12c4acdeb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks closed lower Tuesday as earnings season started with a whimper. Will tomorrow's inflation data provide a positive catalyst?",
                "category": "company",
                "datetime": 1791922130,
                "headline": "Stocks Struggle Ahead of September CPI Report: Stock Market Today"
              },
              {
                "id": 142854423,
                "url": "https://finnhub.io/api/news?id=5bc081dc70d815ffa88823067c5acd0248f42961683e09e9d61876123ee214f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market exclusivity. Both drugmakers point to 2028 as the year that matters. Pfizer is acquiring drugs and cutting costs to bridge the gap, while Bristol Myers still relies on Eliquis, an older drug that continues to grow. So what did each company tell investors at its latest report about how that replacement is going.",
                "category": "company",
                "datetime": 1791921571,
                "headline": "What Does Bristol-Myers Squibb Offer That Pfizer Does Not?"
              },
              {
                "id": 142853456,
                "url": "https://finnhub.io/api/news?id=006e35c542e5af0d0e245a224630268b9a4f84a5ff8cad6e9c0eb2da96c5d9de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index and the State St",
                "category": "company",
                "datetime": 1791920873,
                "headline": "Sector Update: Healthcare Stocks Fall Late Afternoon"
              },
              {
                "id": 142853444,
                "url": "https://finnhub.io/api/news?id=d3c9a96d4f639435dd81c82294ec2c31c03002bcc1a4f295b7f7efba4bcca128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. Justifying that multiple may require sustained growth, yet most of Lilly's sales still come from the company's two dominant blockbusters, Zepbound and Mounjaro. The pharmaceutical maker has a newer drug on sale and expects to launch it in all major markets worldwide in 2027. So what is the new drug, and is it selling.",
                "category": "company",
                "datetime": 1791919463,
                "headline": "What Is Eli Lilly Stock's Biggest Opportunity?"
              },
              {
                "id": 142853114,
                "url": "https://finnhub.io/api/news?id=239f1ec0bd6003c75b83346777ebb77ec584c75f68f4c78fd3f43f5a7e2d2574",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1791918616,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 142853113,
                "url": "https://finnhub.io/api/news?id=3a18440b38bccb051232c611a647e6916b791c40ac5821e8ef45ae23e92a6764",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791918301,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 142852425,
                "url": "https://finnhub.io/api/news?id=6c1c8eece9c7a48faa277d24e0cb29af18551fa74bd010bb9ef46fad03dc7b1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index falling 1.1% and the",
                "category": "company",
                "datetime": 1791913355,
                "headline": "Sector Update: Healthcare Stocks Fall Tuesday Afternoon"
              },
              {
                "id": 142853459,
                "url": "https://finnhub.io/api/news?id=f00b1416751b9b599ae572eb41364da8c22e0580d73153052166dba042a60169",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A decent day for the Dow has completely flipped on its head.",
                "category": "company",
                "datetime": 1791913295,
                "headline": "Here’s What’s Dragging Down the Dow"
              },
              {
                "id": 142852440,
                "url": "https://finnhub.io/api/news?id=8cfb28675f46ce07286b0f66444170846b52486ab25534345d442e7e138366b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) raised its full-year outlook on Tuesday even though the upgraded midpoints m",
                "category": "company",
                "datetime": 1791911468,
                "headline": "Johnson & Johnson's Upgraded Full-Year Outlook Misses Wall Street Views; Stock Declines"
              },
              {
                "id": 142852323,
                "url": "https://finnhub.io/api/news?id=36f94079b9b9aa2fd0130f35dd35b45f854a497f7fa94b27f1ef6a6f9f0786de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson beat earnings this morning. Then its stock price dropped.",
                "category": "company",
                "datetime": 1791911455,
                "headline": "Why Johnson & Johnson Stock Dropped Today"
              },
              {
                "id": 142852442,
                "url": "https://finnhub.io/api/news?id=11d6a2d25a848f4d9c13c5fbbda7602d172acc73e07876725fb84e34cd79a066",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ:NYSE) shares opened down about 4% on Tuesday, October 13, even though the company beat third-quarter estimates and raised its 2026 outlook. Sales rose 5.",
                "category": "company",
                "datetime": 1791911376,
                "headline": "J&J Takes a $5.5 Billion Talc Charge as MedTech Growth Slows From 7.7% to 2.5%"
              },
              {
                "id": 142853426,
                "url": "https://finnhub.io/api/news?id=4edddfecd097c36311f51f264ae0f247e4d9c73a7a3aea3c43334f4a47ace7e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JPMorgan Chase rises slightly as the bank generates $15.3 billion in net income in the third quarter, up 6% from a year earlier.",
                "category": "company",
                "datetime": 1791911100,
                "headline": "JPMorgan Chase, Goldman, Micron, J&J, UnitedHealth, Six Flags, Fermi, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142852319,
                "url": "https://finnhub.io/api/news?id=8df63b35dea60316931d3b06af48196185de99dfb0afd1b29034e70619563639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Moby summary of Johnson & Johnson's Q3 2026 earnings call",
                "category": "company",
                "datetime": 1791910231,
                "headline": "Johnson & Johnson Q3 2026 Earnings Call Summary"
              },
              {
                "id": 142854005,
                "url": "https://finnhub.io/api/news?id=0e72b49acd2a112f103b8185b94b7561369e591feee02199219874754e6d16a9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson is downgraded to a Hold, citing mixed fundamentals and regulatory headwinds. Read more on JNJ stock here.",
                "category": "company",
                "datetime": 1791909976,
                "headline": "Johnson & Johnson: Keep Calm And Hold On"
              },
              {
                "id": 142854006,
                "url": "https://finnhub.io/api/news?id=ba0c4331df9e0f3526ca4a28d4d02c557d5c4b7d8d772c65414b0ee7d7e6629a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) Q3 2026 Earnings Call October 13, 2026 8:30 AM EDTCompany ParticipantsRyan Koors - Vice President of Investor RelationsJoaquin...",
                "category": "company",
                "datetime": 1791909766,
                "headline": "Johnson & Johnson (JNJ) Q3 2026 Earnings Call Transcript"
              },
              {
                "id": 142851845,
                "url": "https://finnhub.io/api/news?id=40d2c5297662fe6576264f21cdd4db7fc189e73028158a4128a0960d9c568eed",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1791909615,
                "headline": "Discover which dow jones stocks are making waves on Tuesday."
              },
              {
                "id": 142851844,
                "url": "https://finnhub.io/api/news?id=7a19a3877cfb0a66a454cc78dcbca0f2fa76447119c7e87a164ed3c33cb12dcc",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1791909301,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 142852405,
                "url": "https://finnhub.io/api/news?id=a12de81a70dd98a6482a8443b9f5dc7a97cf720aa150e6be551c6f5982159af6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Goldman Sachs gains on strong revenue while Johnson & Johnson stumbles on earnings miss, today, Oct. 13, 2026.",
                "category": "company",
                "datetime": 1791909242,
                "headline": "Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading"
              },
              {
                "id": 142852444,
                "url": "https://finnhub.io/api/news?id=5124e749e4f28dee8485bf1a39ea6520ea0b2649a65812abefb3e8ba7d46e053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "For the second straight quarter, the cardiovascular unit experienced slower sales growth due to ongoing struggles in the Abiomed business.",
                "category": "company",
                "datetime": 1791909240,
                "headline": "J&J’s medtech business slows again in Q3"
              },
              {
                "id": 142852438,
                "url": "https://finnhub.io/api/news?id=2f7e6a4106618c1f9aebd240ec47c2298e1504969996f67b0e0a0d005c1b1e92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock is tumbling even after the healthcare giant raised its forecast again for full-year earnings and revenue.",
                "category": "company",
                "datetime": 1791908090,
                "headline": "Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit"
              },
              {
                "id": 142852445,
                "url": "https://finnhub.io/api/news?id=0f593418634b1f38da9c9b0121f98d40c008c06dbafd3236e1cf6192478f351f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 worldwide sales of $25.4 billion, up 6% operationally from a year earlier, as growth in its Innovative Medicine business offset slower-than-expected performance in parts of MedTech. The company raised its full-year sales outlook and said it re",
                "category": "company",
                "datetime": 1791907383,
                "headline": "What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call"
              },
              {
                "id": 142852429,
                "url": "https://finnhub.io/api/news?id=87a8f592063e8d8f81698beef7eb14e7c718f7a31fca261bc50c74fda1a25d52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "All three major US stock indexes were down in late-morning trading Tuesday, as the big banks kicked",
                "category": "company",
                "datetime": 1791907259,
                "headline": "Top Midday Stories: JPMorgan Shares Rise Despite Q3 Miss; J&J EPS Guidance Undershoots Estimates, Shares Fall"
              },
              {
                "id": 142852447,
                "url": "https://finnhub.io/api/news?id=b8888ffa85a9344aa0d018e40b4759dea9f16beef85c58fcef0593c0a75c60d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Despite several products succumbing to generics and biosimilars, J&J raised its 2026 guidance.",
                "category": "company",
                "datetime": 1791905678,
                "headline": "Tremfya rescues J&J’s immunology sales to fuel strong Q3"
              },
              {
                "id": 142853188,
                "url": "https://finnhub.io/api/news?id=9a894c7153c7c5a5dc9fc1509910af2be7ed4f705868ee5b7142cb34ac249826",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395728828/image_1395728828.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "JPMorgan misses earnings forecasts as big banks kick off reporting. UnitedHealth raises its full-year outlook for the third time. Fund managers pile into tech stocks.",
                "category": "company",
                "datetime": 1791905280,
                "headline": "Wall Street Lunch: Bank Earnings Nothing To Write Home About"
              },
              {
                "id": 142884223,
                "url": "https://finnhub.io/api/news?id=7a5ad28d76d10852ff004cc3d8da94e1d7c5499280f632a8e37ca8e39d3d263b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Johnson--Johnson.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.",
                "category": "company",
                "datetime": 1791904642,
                "headline": "Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)"
              },
              {
                "id": 142851174,
                "url": "https://finnhub.io/api/news?id=aa1899491622c27545081c5e816f7c2f7b2471db200bc58816b0c744d4f5e4df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "On this episode of Stock Movers: - Domino's Pizza (DPZ) shares are lower after the restaurant chain reported total domestic stores comp sales growth for the third quarter that missed the average analyst estimate. - Johnson & Johnson (JNJ) shares are moving as the company reports earnings. J&J raised its profit guidance as demand for newer drugs in cancer and autoimmune diseases overshadowed more anemic growth in the company's medical device business. - Bumble (BMBL) shares are halted on news Ithaca is taking Bumble private for $1.3 billion, with a deal price of $6.05 per share. Bumble founder Whitney Wolfe Herd said she would \"remain actively involved with Bumble\" after the deal, which marks a significant change for the company that was valued at $14 billion when it went public.",
                "category": "company",
                "datetime": 1791904301,
                "headline": "Domino's Drops on Sales Growth Miss; Bumble Goes Private | Stock Movers"
              },
              {
                "id": 142886102,
                "url": "https://finnhub.io/api/news?id=146c8721dcdd6236564c2d1221ca173aa37bc0b21d39656fd506bb2389da7cfe",
                "image": "https://image.cnbcfm.com/api/v1/image/108404600-17919179201791917917-48978672239-1080pnbcnews.jpg?v=1791917919&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock is tumbling despite the company raising its forecast again for full-year earnings and revenue.",
                "category": "company",
                "datetime": 1791903720,
                "headline": "Johnson & Johnson shares fall following earnings"
              },
              {
                "id": 142851171,
                "url": "https://finnhub.io/api/news?id=e6f6e230d012dca8f1975409c04e930363baf85a061aa1167fe9f403dd5c703c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reported quarterly earnings on Tuesday and raised its full-year outlook. Johnson & Johnson CFO Joseph Wolk sits down with Yahoo Finance's Julie Hyman to discuss the company's strong drug sales numbers, highlighting the excitement surrounding two medications in particular.",
                "category": "company",
                "datetime": 1791903067,
                "headline": "Why this drug could become 'better than a $10B product': Johnson & Johnson CFO"
              },
              {
                "id": 142850488,
                "url": "https://finnhub.io/api/news?id=251766da1e5b52b9f8d9aa0b816bae4f1afe5880c09586fb51895499921bf780",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1791902101,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 142884224,
                "url": "https://finnhub.io/api/news?id=719ff604dd38660ec8fb353be44fa9fbcf94b856c4babbe5c8f6ac82d88f8419",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson beat third-quarter profit estimates and raised its 2026 forecast. After MedTech sales missed estimates, the stock still fell about 6%, its steepest one-day drop since April 1, 2025. XLV fell 1.1%.",
                "category": "company",
                "datetime": 1791901413,
                "headline": "QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss"
              },
              {
                "id": 142851172,
                "url": "https://finnhub.io/api/news?id=e6c93de879bd1e240678756df59ef9cb50f1e994b830861f4b44f9f2fea8aba2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ), the healthcare group, raised its 2026 sales and earnings forecasts after third-quarter sales grew 6% on an operational basis, supported by its medicines business and new products. The company increased its estimated full-year reported sales midpoint to $101.2...",
                "category": "company",
                "datetime": 1791901020,
                "headline": "Johnson & Johnson raises 2026 guidance as quarterly sales climb"
              },
              {
                "id": 142851163,
                "url": "https://finnhub.io/api/news?id=943b0302e7c375c0a2acdd83ab73d9ab7f18e9f8d20f659b3155809d23294c03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Small-Business Optimism Dips in September.",
                "category": "company",
                "datetime": 1791900300,
                "headline": "Small-Business Optimism Dips in September"
              },
              {
                "id": 142848697,
                "url": "https://finnhub.io/api/news?id=bafdb7e238fe80bcc36848ee70993334dcbad5aa7f0088c3c52e48a70ef0b8bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The 8:30 Hosts Julie Hyman, Jake Conley, and Pras Subramanian tackle the day's biggest news stories, including earnings out from major bank stocks, Anthropic's (ANTH.PVT) latest warning on AI replication, and Bumble's (BMBL) latest pivot to go private.",
                "category": "company",
                "datetime": 1791899895,
                "headline": "Big Banks out with earnings, J&J boosts outlook, Anthropic's latest AI warning"
              },
              {
                "id": 142851173,
                "url": "https://finnhub.io/api/news?id=52bfecf14db533640a6652f9c607209b6c62d00634d3c8f1b4329f11c77aa85b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.",
                "category": "company",
                "datetime": 1791899820,
                "headline": "J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down"
              },
              {
                "id": 142851128,
                "url": "https://finnhub.io/api/news?id=26cb7d518178ceaebf51938cf13a62a562cc82df6be6def400614f846308b8ef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JPMorgan Chase rises as the bank generates $15.3 billion in net income in the third quarter, up 6% from a year earlier.",
                "category": "company",
                "datetime": 1791899760,
                "headline": "JPMorgan Chase, Goldman Sachs, J&J, UnitedHealth, Six Flags, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 142848519,
                "url": "https://finnhub.io/api/news?id=76e2ce766cd71affb2652c8283039f2145199b8a758298e59a856e490666934f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stocks were mixed on Tuesday as big banks kicked off earnings season.",
                "category": "company",
                "datetime": 1791899741,
                "headline": "Bank stocks rise on JPMorgan, Goldman earnings as chip stocks fall: AlphaCheck"
              },
              {
                "id": 142848687,
                "url": "https://finnhub.io/api/news?id=3c25db6985dc40c9e21d1de63f929dddf71131ea2877cfa06d2a21316cf91fda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) continues its hot streak as the pharmaceutical giant has raised its full-year outlook. The 8:30 Hosts, Julie Hyman, Jake Conley, and Pras Subramanian, take a deeper look at what drove this quarter's success.",
                "category": "company",
                "datetime": 1791898740,
                "headline": "Johnson & Johnson raises full-year outlook as momentum builds"
              },
              {
                "id": 142882290,
                "url": "https://finnhub.io/api/news?id=dad524e982dd6c58bdb1fa3180264aef3534e3fa2d3d927ace66c7ffc4b03f05",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1791898511,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142884226,
                "url": "https://finnhub.io/api/news?id=6a1fe60a473436de9b853b9971ec973c93a2a0434f5d6ac703ed82418c1a8b4b",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.wsj.com/business/earnings/j-j-is-leaning-toward-spinning-out-its-hips-and-knees-business-0de8d70d",
                "category": "company",
                "datetime": 1791897889,
                "headline": "'J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business' - The Wall Street Journal"
              },
              {
                "id": 142848688,
                "url": "https://finnhub.io/api/news?id=f269e0d4d52d8b97f11f780ea450d152b29aa83168135f046ba537d2fefa2b70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Updates with CFO comments on planned spinoff of orthopedics unit in sixth paragraph, updates stock",
                "category": "company",
                "datetime": 1791897544,
                "headline": "Update: Johnson & Johnson Fiscal Q3 Adjusted Earnings Fall, Sales Increase; Fiscal 2026 Guidance Lifted"
              },
              {
                "id": 142848695,
                "url": "https://finnhub.io/api/news?id=061d706d37a381f2bc6d4446dffb372ec4d344b9ca330fcf6725dd5aecdc6900",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Skipping bonds in retirement sounds reckless, but a growing number of retirees are building six-figure income portfolios without a single Treasury note. The question is whether the yield is worth the risk hiding inside this strategy.",
                "category": "company",
                "datetime": 1791897443,
                "headline": "$8,550 a Month and Zero Bonds: The Dividend Portfolio Retirees Are Building Instead"
              },
              {
                "id": 142851177,
                "url": "https://finnhub.io/api/news?id=cdb5a8ebb4149139e5d95942fa8f10ddf49b2fe2f69a5bb311ec7f8be5b2cf08",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While JPM missed Q3 estimates, GS posted a strong quarter, with WFC somewhat in between.",
                "category": "company",
                "datetime": 1791897240,
                "headline": "Mixed Pre-Markets Greet Fresh Q3 Earnings Reports"
              },
              {
                "id": 142848596,
                "url": "https://finnhub.io/api/news?id=49ec050c905a6901984cd922e91ad3778b7449e9af85b15c971c333bb6b9f185",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "VYM's trailing yield sits well below what a 10-year Treasury pays today, yet the fund keeps attracting billions in new assets. The reason comes down to what bonds cannot offer and what income investors often overlook when comparing the two.",
                "category": "company",
                "datetime": 1791897191,
                "headline": "How VYM’s $94.6B Dividend Kings Aided Portfolio Is Beating Treasuries"
              },
              {
                "id": 142851945,
                "url": "https://finnhub.io/api/news?id=3125300c21444d074975cf3a7de6d07ce0a736e19c53aaa6cdbfdf2241914ec4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2264783286/image_2264783286.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson Q3 2026: revenue up 6%, but EPS fell, and shares slid 5% amid a $5.5B talc reserve. Click for this JNJ earnings update and see if it is right for you.",
                "category": "company",
                "datetime": 1791897064,
                "headline": "Johnson & Johnson Q3 Earnings: Talc Resolution Offer Impacts Earnings, MedTech Slows Growth"
              },
              {
                "id": 142882264,
                "url": "https://finnhub.io/api/news?id=87996aeb9140c87eebdff207bb0e9a303700c7fad94716a315ca0dc338a1f6a5",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/National-Flag-Of-South-Korea-On-Satin--D.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Chip stocks sold off after a 5% KOSPI plunge, with Micron and Applied Materials sinking, while J&J fell despite a guidance raise.",
                "category": "company",
                "datetime": 1791896361,
                "headline": "Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today"
              },
              {
                "id": 142848689,
                "url": "https://finnhub.io/api/news?id=a7f07420f388976ee839cc1ece6a8af58706ea70b40c352f209d00b73669432e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighted on medical device sales.",
                "category": "company",
                "datetime": 1791896079,
                "headline": "Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech Sales"
              },
              {
                "id": 142848690,
                "url": "https://finnhub.io/api/news?id=22661ca91e6d4fdae154b124a167e388dfe07dab96756e6ea51d46f44cba6300",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 earnings and revenue above Wall Street expectations on Tuesday, supported by growth in its Innovative Medicine business and continued expansion across its medical technology operations. The US healthcare company posted adjusted earnings per share of $2.",
                "category": "company",
                "datetime": 1791895102,
                "headline": "Johnson & Johnson Beats Third-Quarter Earnings Estimates and Raises 2026 Revenue and Profit Outlook"
              },
              {
                "id": 142848691,
                "url": "https://finnhub.io/api/news?id=2739f3567089a2f53570186d934803805202ae2c0822726d594f5d45cf89986e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in Johnson & Johnson (JNJ). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1791894604,
                "headline": "Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?"
              },
              {
                "id": 142848692,
                "url": "https://finnhub.io/api/news?id=8394c5028d631cf4b3a20a9659b2232bf5c7c5536da4af6c9301615e4afb02aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1791894603,
                "headline": "Compared to Estimates, Johnson & Johnson (JNJ) Q3 Earnings: A Look at Key Metrics"
              },
              {
                "id": 142848694,
                "url": "https://finnhub.io/api/news?id=c61e0f04036f0b58c396acd06048b9916974ea6adc7ddf264abf01aef6c3af79",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "News of the day for Oct. 13, 2026",
                "category": "company",
                "datetime": 1791894384,
                "headline": "5 Things to Know Before the Stock Market Opens on Tuesday"
              },
              {
                "id": 142851558,
                "url": "https://finnhub.io/api/news?id=f0f4f28d73096cd1c87c228f4068b9508c27abdd5e3912e8c570d930aa0e1bd3",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "2026-10-13. The following slide deck was published by Johnson & Johnson in conjunction with their 2026 Q3 earnings call.",
                "category": "company",
                "datetime": 1791892858,
                "headline": "Johnson & Johnson 2026 Q3 - Results - Earnings Call Presentation"
              },
              {
                "id": 142847447,
                "url": "https://finnhub.io/api/news?id=015e7383933811c6d811368ba6c824d515f24833a2b9918d49387afb3a742407",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Big bank results kick off Q3 earnings season on Tuesday.",
                "category": "company",
                "datetime": 1791892295,
                "headline": "Earnings live updates: JPMorgan, Goldman Sachs stocks rise as big banks kick off Q3 earnings season"
              },
              {
                "id": 142847358,
                "url": "https://finnhub.io/api/news?id=9328fa0cab3286cc651f7448b00e2e8188e5e7ff7ac8ffa01eda5c724ff2fe91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The stock market is reacting to big bank earnings, Micron gets a warning from Elon Musk about Chinese memory chips, and more news to start your day.",
                "category": "company",
                "datetime": 1791892140,
                "headline": "Tech Selloff Deepens as Bank Earnings Fuel Stock Market Rotation"
              },
              {
                "id": 142848693,
                "url": "https://finnhub.io/api/news?id=7080d2487b8b3fdcccce025d594bca2057f3180dcc75b63ffdae05b01fe4c4a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.",
                "category": "company",
                "datetime": 1791890940,
                "headline": "Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?"
              },
              {
                "id": 142847438,
                "url": "https://finnhub.io/api/news?id=5ca427a413013f1310f27e9da9e339f0b0d66ee91b221c2ffe3c120e660d15d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.",
                "category": "company",
                "datetime": 1791890940,
                "headline": "Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble. Stock Falls."
              },
              {
                "id": 142846264,
                "url": "https://finnhub.io/api/news?id=01842588225a0075aa72ecd6ed31cc56adcfc8b349540f3e23caace88b45fe80",
                "image": "https://www.chartmill.com/images/uploads/earnings_article_1_defce97180.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Johnson & Johnson Q3 2026 earnings in line, revenue slightly misses; MedTech lags, full-year guidance raised, shares fall premarket.",
                "category": "company",
                "datetime": 1791890509,
                "headline": "Johnson & Johnson (NYSE:JNJ) Q3 2026: In-Line Results and Raised Guidance Offset by MedTech Weakness"
              },
              {
                "id": 142847064,
                "url": "https://finnhub.io/api/news?id=7904d19df5d22d641515a8b1eab78ffbecd1c0110d5f88c730c01a7a90d8567e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wall Street futures were mixed on the downside pre-bell Tuesday as traders digested big bank earning",
                "category": "company",
                "datetime": 1791890282,
                "headline": "Bank Bank Earnings, Chip Drama Roil Wall Street Pre-Bell; Asia Mixed, Europe Up"
              },
              {
                "id": 142850826,
                "url": "https://finnhub.io/api/news?id=b28ee841bb547fcc26557c569a6277ea410bc5cb494ceea2f398caae2601e85a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Charts-Of-Financial-Instruments-With-Var.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Four sectors are higher and seven are lower in Tuesday’s regular session, with cyclical sectors holding two of the top three positions. Materials sits well clear of the lower group, separated by a margin several times wider than any other gap in the table.",
                "category": "company",
                "datetime": 1791889260,
                "headline": "Cyclicals Lead Sectors In Tuesday Trading As Health Care Trails"
              },
              {
                "id": 142845712,
                "url": "https://finnhub.io/api/news?id=d2ce8c34f048852c9a505645e115466792f4b8414f2d7c8bbbe0b9617c0a2f83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Johnson & Johnson (NYSE: JNJ) reported its latest quarterly results ahead of the open on Tuesday, exceeding analyst expectations.",
                "category": "company",
                "datetime": 1791889203,
                "headline": "Johnson & Johnson beats estimates, raises 2026 guidance"
              },
              {
                "id": 142847441,
                "url": "https://finnhub.io/api/news?id=262c13b238ce81163c22a26f3f6904aabad4e33a7e58302516fa88e16ef4eacb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.37% and -0.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1791888302,
                "headline": "Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates"
              },
              {
                "id": 142847448,
                "url": "https://finnhub.io/api/news?id=32cae84453534a6865f31465092e580c4896eeb8d4d304824204388d8001859f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stock futures were mixed Tuesday as several big banks and other notable companies reported quarterly results, with shares of memory chip makers falling for a second straight day on worries about Chinese competition.",
                "category": "company",
                "datetime": 1791888049,
                "headline": "Stock Market Today: Futures Mixed on Busy Earnings Day; Dow Lifted by UnitedHealth; Memory Stocks Weigh on Nasdaq"
              },
              {
                "id": 142845713,
                "url": "https://finnhub.io/api/news?id=1e4e2e4ef24859df579eec5c2b3c2b016d2b723c19b1d29281877f3e2814f966",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(AP) — Johnson & Johnson (JNJ) on Tuesday reported third-quarter profit of $210 million.On a per-share basis, the New Brunswick, New Jersey-based company said it had profit of 9 cents.",
                "category": "company",
                "datetime": 1791887843,
                "headline": "Johnson & Johnson: Q3 Earnings Snapshot"
              },
              {
                "id": 142845714,
                "url": "https://finnhub.io/api/news?id=80743ca7ccc20ed71a425aa116b3ae8099a98e928dc1db1f7c36a9dd7657a02e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., October 13, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026.",
                "category": "company",
                "datetime": 1791887100,
                "headline": "Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026"
              },
              {
                "id": 142845715,
                "url": "https://finnhub.io/api/news?id=4ee0f4a73220fbeb6090dc2b77490e7665a6355c980d2cc87235cca14ad23f67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Company Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as rep",
                "category": "company",
                "datetime": 1791886920,
                "headline": "Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026"
              },
              {
                "id": 142849505,
                "url": "https://finnhub.io/api/news?id=defaa3e331378153469c423e55432318028bc1e9ea1333297a8015e96e89a4ce",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) held its third-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.\nThis transcript is brought to you by Benzinga APIs. For real-time access to",
                "category": "company",
                "datetime": 1791884820,
                "headline": "Transcript: Johnson & Johnson Q3 2026 Earnings Conference Call"
              },
              {
                "id": 142843034,
                "url": "https://finnhub.io/api/news?id=96f2a79e932212352dcef0bbfe0318e632bad9a4b86bc98d14953455d773f360",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has delivered strong returns in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today. Recent drug data and pipeline headlines keep attention on the story, but the real issue for investors is what those developments mean for long term cash flows. Over the past 5 years, Johnson & Johnson has returned 89.4%, which puts a lot of accumulated optimism on the line if its future cash generation falls...",
                "category": "company",
                "datetime": 1791882705,
                "headline": "Johnson & Johnson (JNJ) Stock May Be 28% Undervalued As TREMFYA Data Impresses"
              },
              {
                "id": 142849506,
                "url": "https://finnhub.io/api/news?id=0f6cd57d2e6fb6db125a0bec818b20bb72e883ec32d5008263944e5e850fa177",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "-Conference Call. ",
                "category": "company",
                "datetime": 1791882299,
                "headline": "Johnson & Johnson Says We Remain On Track For The Planned Separation Of Depuy Synthes By Mid 2027"
              },
              {
                "id": 142839966,
                "url": "https://finnhub.io/api/news?id=fa46466387e74459886e2c10751d745820c496b1961be3ecb7e7e2a997a56b96",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "On Stocktwits, retail sentiment toward SPY and QQQ has remained ‘bullish’.",
                "category": "company",
                "datetime": 1791880650,
                "headline": "Nasdaq Futures Sink, Dow Rises Premarket As AI Chip Stocks Wobble Ahead Of Big Bank Earnings: MU, SNDK, NVTS, NVDA, SPCX, ASTS, UNH, V Stocks In Focus"
              },
              {
                "id": 142847706,
                "url": "https://finnhub.io/api/news?id=e78dc583ae84fcd0893ea6e05db8e4597c5370b14ff10c0ed039b866b7ed0385",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/825526728/image_825526728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend Aristocrats and Dividend Kings are popular for good reason, but their impressive track records can create a dangerous false sense of security.",
                "category": "company",
                "datetime": 1791878700,
                "headline": "The Most Important Dividend Investing Lesson I've Ever Learned"
              },
              {
                "id": 142852051,
                "url": "https://finnhub.io/api/news?id=a08dc994f4685c828ec50c7b93ccf29ac57a71b89b98cda7630a0f660f63f10a",
                "image": "https://image.cnbcfm.com/api/v1/image/108402711-17918889961791888992-48971327504-1080pnbcnews.jpg?v=1791888994&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, spin off of its hips and knees business, company growth outlook, and more.",
                "category": "company",
                "datetime": 1791875784,
                "headline": "Johnson & Johnson CFO Joseph Wolk on the company’s Q3 results"
              },
              {
                "id": 142848354,
                "url": "https://finnhub.io/api/news?id=6712d1a101f47e12dc784623fb5832135bbe2b253aad7f0c6df29a384b68cc32",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_scheduled_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Companies Reporting Before The Bell\n• Unity Bancorp (NASDAQ:UNTY) is likely to report quarterly earnings at $1.55 per share on revenue of $35.60 million. \n• JPMorgan Chase (NYSE:JPM) is projected to report quarterly",
                "category": "company",
                "datetime": 1791875464,
                "headline": "Earnings Scheduled For October 13, 2026"
              },
              {
                "id": 142849508,
                "url": "https://finnhub.io/api/news?id=7f299953e8a17242aef177362a0cdb2a95a86f2ded404a2c9b07288fbea40b8a",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 analyst estimate. Raises FY2026 sales outlook from $100.800 billion-$101.400 billion to $101.000",
                "category": "company",
                "datetime": 1791872524,
                "headline": "Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est"
              },
              {
                "id": 142832171,
                "url": "https://finnhub.io/api/news?id=daa5ba8aa9b20902d5ae142ea94e15b7ed22a1a8ab9871e0907d8d97a477985c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "HONG KONG (AP) — South Korea’s benchmark Kospi index dropped more than 7% on Tuesday on a sell-off of chip shares, and Asian shares mostly declined after U. futures were also mixed, and oil prices fell as escalating tensions in the Middle East continued.",
                "category": "company",
                "datetime": 1791860166,
                "headline": "South Korea's Kospi index sinks more than 7% on semiconductor share sell-off over AI boom worries"
              },
              {
                "id": 142848478,
                "url": "https://finnhub.io/api/news?id=8229a7a2a9fa89cc3a982e2c13022dd56a36f2cb18b69b4e232d9fb5e0859c35",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/Stock-S-And-P-500-Index-Fund-Symbol-Is-O.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Will S&P 500 open higher? Polymarket odds dip to 37% as Wall Street faces a Nasdaq selloff, Q3 bank earnings and Trump's new energy policies.",
                "category": "company",
                "datetime": 1791856121,
                "headline": "Stock Market: Will S&P 500 Open Up or Down Today?"
              },
              {
                "id": 142848479,
                "url": "https://finnhub.io/api/news?id=045a43f19aeec9dbed8d6313331a172b87cfdf824d25ac498c0dd8fc2ba495d5",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/13/New-York--Usa--May-31--2023-J-p-morgan-B.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "JPMorgan, J&J, Goldman Sachs, Wells Fargo and Citi are set to report quarterly earnings before Tuesday’s open; shares edge higher after-hours.",
                "category": "company",
                "datetime": 1791852225,
                "headline": "JPMorgan, Goldman Sachs and 3 Stocks to Watch Heading Into Tuesday"
              },
              {
                "id": 142825557,
                "url": "https://finnhub.io/api/news?id=0ed83cae897d5328a440303c15e0d102a8864a028c818d7dfc195d227dedb301",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Market Domination Overtime host Brooke DiPalma takes a closer look at the top stories for investors to watch on Tuesday, October 13, including earnings reports from JPMorgan Chase (JPM), The Goldman Sachs Group (GS), Wells Fargo & Company (WFC), and Citigroup (C), Johnson & Johnson (JNJ) delivers its earnings reports, and the release of home sales data for September.",
                "category": "company",
                "datetime": 1791849600,
                "headline": "Earnings from banks and  J&J and home sales data: What to Watch"
              },
              {
                "id": 142824534,
                "url": "https://finnhub.io/api/news?id=b9d663d4e14ac1ed4d82bfde16d662ad78cb813f058557513759e39941946518",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA® (guselkumab) across clinically important subgroups of adults with Crohn's disease with perianal fistula.1 The prespecified subgroup analyses from the FUZION study are being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and build on previously reported Week 24 results from the overall study population.",
                "category": "company",
                "datetime": 1791835500,
                "headline": "New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups"
              },
              {
                "id": 142824533,
                "url": "https://finnhub.io/api/news?id=600278e63fdc1879e283fe7a2110f745bcd417f4f0512d611d90dd3014612bfc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA® (guselkumab) in adults with moderately to severely active Crohn's disease.1 The Week 144 long-term extension (LTE) results being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting reveal long-term clinical and endoscopic outcomes across both TREMFYA maintenance regimens in this chron",
                "category": "company",
                "datetime": 1791835500,
                "headline": "TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease"
              },
              {
                "id": 142822713,
                "url": "https://finnhub.io/api/news?id=5b549af35f8c34e8aff5bf2125e0b56139f22e32e5010a2ac3f69e489b9878c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Medtronic (MDT) stock trades at 21.6 times earnings, sitting about level with the S&P 500 at 21.9. Shareholders paying that market price need to know what they are buying, particularly as corporate priorities shift. During its fiscal Q2 2025 call in November 2024, management first reviewed its fastest-growing businesses, including cardiac ablation, before turning to its established market leaders. Now, the company leads with something newer. So what is Medtronic putting first today.",
                "category": "company",
                "datetime": 1791825387,
                "headline": "Has Medtronic Stock Become A Different Bet?"
              },
              {
                "id": 142822711,
                "url": "https://finnhub.io/api/news?id=4c955df73a5870ac01a4bfb542467101453f7ed4a3e4ac340997fd39304a05af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.",
                "category": "company",
                "datetime": 1791822002,
                "headline": "Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142822712,
                "url": "https://finnhub.io/api/news?id=e7179d9a62f767acdac207284fd7773ff9f6ce303a3aaa8d0d8025b494f8177a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stryker, which has been looking to get into the soft tissue robotics market for years, is now positioned to compete with new entrants Johnson & Johnson and Medtronic.",
                "category": "company",
                "datetime": 1791821765,
                "headline": "Stryker enters soft tissue robotics with $400M investment in CMR Surgical"
              },
              {
                "id": 142849511,
                "url": "https://finnhub.io/api/news?id=667c69ed0bf49cb10bee1b0b99777b16d0be6fefa3cd8ae4ab5fd7fbb68b7a54",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA® (guselkumab) in adults with moderately",
                "category": "company",
                "datetime": 1791821526,
                "headline": "Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease"
              },
              {
                "id": 142848480,
                "url": "https://finnhub.io/api/news?id=dd14f31f514251cfc8f3e37ba702289268de795eae0fb8d9d0bd7c1600c2d822",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Earnings-Season-Written-In-Search-Bar-Wi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "UnitedHealth, JPMorgan Chase, Wells Fargo, Goldman Sachs and Citigroup report earnings Tuesday. See implied moves and market value at stake.",
                "category": "company",
                "datetime": 1791819012,
                "headline": "JPMorgan Chase Could Swing $28 Billion After Earnings"
              },
              {
                "id": 142821607,
                "url": "https://finnhub.io/api/news?id=ec6b899d8677cc971c4128635ebd24145e6368a585d1c01f876ab504597c907a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the immunology market.",
                "category": "company",
                "datetime": 1791814620,
                "headline": "Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?"
              },
              {
                "id": 142821612,
                "url": "https://finnhub.io/api/news?id=b1e5da76f8d31fddfef9b45f7d575c9268ebad0db9030f31463f4e83b2048c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "It's the biggest week for market news in more than a month: Q3 earnings and both CPI and PPI inflation reports for September.",
                "category": "company",
                "datetime": 1791810660,
                "headline": "Big Week of Data: Inflation & Q3 Earnings"
              },
              {
                "id": 142819921,
                "url": "https://finnhub.io/api/news?id=ff4531aaa4b116b1965b2521a16585e36eb4fee64b87909dc3dccf7207f5fb04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1791809664,
                "headline": "Update: US Equity Futures Mostly Flat Pre-Bell Ahead of Week of Earnings, Economic Data"
              },
              {
                "id": 142819917,
                "url": "https://finnhub.io/api/news?id=aff5febfc500b546b673c5e39ae588b0b0b883fcb9dd6e3921c5969b0ee4d723",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replacing a blockbuster is the hardest job in the drug business. Johnson & Johnson (NYSE:JNJ) is in the middle of it, and the scoreboard looks oddly calm. In the second quarter of 2026, Stelara, its psoriasis and Crohn’s disease drug now facing cheaper biosimilar copies, dragged the pharmaceutical unit’s growth down by about 760 basis […]",
                "category": "company",
                "datetime": 1791808568,
                "headline": "Johnson & Johnson (JNJ) Survived the Stelara Cliff. Is 23.6 Times Earnings Too Much?"
              },
              {
                "id": 142848483,
                "url": "https://finnhub.io/api/news?id=9975abe42719cf527d534ac55990d75eee810a6a85467d61b7bcf5414584fb4d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Tallinn--Estonia---August-4th-2023---Scr.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Five of the 30 Dow Jones Industrial Average components report earnings this week. Here are the names.",
                "category": "company",
                "datetime": 1791807859,
                "headline": "Dow Jones Industrial Average Gets Spotlight: 5 Earnings Reports Representing 25% of ETF’s Assets On Deck"
              },
              {
                "id": 142819918,
                "url": "https://finnhub.io/api/news?id=1b28cb067f28d3d31b340807fba53b09f6606edf6d9a520d5da66eef5568fff7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Treasury bills guarantee your rate until maturity while Johnson and Johnson has raised its dividend for 64 straight years, but depending on your tax state and timeline, one of these income streams quietly keeps far more money in your pocket than the raw yield suggests.",
                "category": "company",
                "datetime": 1791807354,
                "headline": "Treasury Bills vs Dividend Stocks: Which Income Stream Actually Fits Your Retirement"
              },
              {
                "id": 142819919,
                "url": "https://finnhub.io/api/news?id=cdbc5949bbe7e014b8c1a6b060c31027e05cbe1b5a1d7a46fc87ec1b185633d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson is due to report earnings Tuesday morning, with traders expecting a move that could bring the stock back near its recent record.",
                "category": "company",
                "datetime": 1791806400,
                "headline": "Here’s How Much Johnson & Johnson Stock Is Expected to Move After Earnings"
              },
              {
                "id": 142819243,
                "url": "https://finnhub.io/api/news?id=5c3bcce85121fbb5ed8e429ebbf338c68840af084cee2f3d7336c076481e4cbd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US equity futures were mostly unchanged pre-bell Monday ahead of a week filled with a slew of earnin",
                "category": "company",
                "datetime": 1791806197,
                "headline": "US Equity Futures Mostly Flat Pre-Bell Ahead of Week of Earnings, Economic Data"
              },
              {
                "id": 142819100,
                "url": "https://finnhub.io/api/news?id=c90725692a4a00d579f74c9c926c9e0d4ea2ca5676e0f87549d99e7a5c99f2c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The benchmark US stock measures were mostly pointing higher before the opening bell Monday as trader",
                "category": "company",
                "datetime": 1791805985,
                "headline": "Stocks Mostly Up Pre-Bell as Traders Await Latest Earnings, Key Inflation Data"
              },
              {
                "id": 142819880,
                "url": "https://finnhub.io/api/news?id=90a8c1ac6c93e9f26cae87a2cdf1a81e3ad7b5a6b07d92e9b5fec3a5eca8621e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JPMorgan, Citigroup, Pepsi, Micron and Nike headline Zacks' earnings preview as rising estimates signal broad-based Q3 growth, while surging Treasury yields pressure banks.",
                "category": "company",
                "datetime": 1791805800,
                "headline": "JPMorgan, Citigroup, Pepsi, Micron and Nike are part of Zacks Earnings Preview"
              },
              {
                "id": 142819101,
                "url": "https://finnhub.io/api/news?id=54736cbeaefed46bba02a4ac86fc29f9f94b9a209d2a5a517bddbdd098ff970f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two healthcare giants drop their third-quarter numbers on the same morning, and what each reveals about drug costs, insurance margins, and guidance ranges will set the tone for the entire sector heading into 2027.",
                "category": "company",
                "datetime": 1791804915,
                "headline": "Johnson & Johnson and UnitedHealth Report the Same Morning. Here’s What Matters."
              },
              {
                "id": 142818995,
                "url": "https://finnhub.io/api/news?id=a0322560b8e7f90c21b9ad6b298aad238f6dff74eb86d9dc9103144495942531",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "American News Group News Commentary - The S&P 500 set an all-time high on Tuesday, October 6, and finished the week at 7,811.54 after a Friday gain of 0.6%, with the Dow Jones Industrial Average closing at 51,654.95 and the Nasdaq Composite at 27,366.17. All three finished the week higher, even as the 10-year Treasury yield recently reached its highest level since 2002 and closed Friday at 5.24%. The most active names of the week moved on company news: a satellite spectrum deal that hit wireless",
                "category": "company",
                "datetime": 1791804540,
                "headline": "After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports"
              },
              {
                "id": 142819102,
                "url": "https://finnhub.io/api/news?id=e212ee45f002682a5b81167a762d407d5a582da310cd6269c53276f8953207c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wall Street futures were mixed and muted pre-bell Monday as traders awaited the start of earnings se",
                "category": "company",
                "datetime": 1791803022,
                "headline": "Earnings Season, Oil, Bonds Pressure Wall Street Pre-Bell; Asia Mixed, Europe Up"
              },
              {
                "id": 142823677,
                "url": "https://finnhub.io/api/news?id=cdfd8873982c444f5a916ef4f201446a81e418562d2775251baf3a6de360a8a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Major U.S. stock indexes were mixed Monday to begin a big week of bank earnings and inflation reports, while the U.S. bond market was closed.",
                "category": "company",
                "datetime": 1791802232,
                "headline": "Stock Market Today: Dow Rises, Nasdaq Slips to Start Begin Big Week of Earnings; Bond Market Closed Today"
              },
              {
                "id": 142811098,
                "url": "https://finnhub.io/api/news?id=cbf7f6a75403cd98f115fef65569d3af6e7184cb8fd8be23303f58292f27882c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.",
                "category": "company",
                "datetime": 1791771434,
                "headline": "Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist"
              },
              {
                "id": 142809116,
                "url": "https://finnhub.io/api/news?id=64d8530632a1b2730bcee39b079b5edd6fc2aaec9cb38acae1124001bb5184cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) subsidiary Atraverse Medical has been sued by Boston Scientific over alleged patent infringement tied to a cardiology device. The complaint focuses on technology used in a key heart procedure tool that Boston Scientific claims is protected by its existing patents. Boston Scientific is seeking court relief that could affect Atraverse Medical's ability to make or sell the contested device. The Boston Scientific lawsuit against Atraverse Medical adds a fresh legal...",
                "category": "company",
                "datetime": 1791756646,
                "headline": "Is Johnson & Johnson (JNJ) Facing New MedTech Risk After A Patent Lawsuit?"
              },
              {
                "id": 142807825,
                "url": "https://finnhub.io/api/news?id=f925430941324f14560ce9a9de86d41b781d6888c52ada174caea1161be6ff68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Six holdings, no yield traps, and a monthly income target that demands you bring serious capital to the table. The real question is whether each payout can actually hold up when occupancy slips, cash flow disappoints, or litigation lands.",
                "category": "company",
                "datetime": 1791743848,
                "headline": "Could You Live on $6,750 a Month in Dividends? What It Takes, Without a Single Yield Trap"
              },
              {
                "id": 142807823,
                "url": "https://finnhub.io/api/news?id=bde8615a51b17182004a12c37ab4ccd86b7c826ca8b11ea173dd1397954f79f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Big bank earnings arrive, with Citi, Goldman Sachs, JPMorgan Chase, and more reporting. Consumer and producer price indexes and existing home sales data will provide a read on the economy.",
                "category": "company",
                "datetime": 1791741600,
                "headline": "Wells Fargo, Bank of America, Domino’s, Johnson & Johnson, Inflation Data, and More to Watch This Week"
              },
              {
                "id": 142807824,
                "url": "https://finnhub.io/api/news?id=260766c8a107620f201989949cb18acce1a58bea0794b6e2b83a2530b8d3732e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson will report its third-quarter results on Oct. 13.",
                "category": "company",
                "datetime": 1791725757,
                "headline": "Dear Johnson & Johnson Stock Fans, Mark Your Calendars for October 13"
              },
              {
                "id": 142806923,
                "url": "https://finnhub.io/api/news?id=0e1f88e32d684ef29a5ec2cd4b8e528f14b92837c8da37909f2d611a40cee4d4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2199578213/image_2199578213.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "JPMorgan, Goldman Sachs and other big banks launch earnings season. CPI hits as yields hit two-decade highs. Trump announces an energy ceasefire between Russia and Ukraine.",
                "category": "company",
                "datetime": 1791725340,
                "headline": "Wall Street Brunch: Start Your Earnings Engines"
              },
              {
                "id": 142805424,
                "url": "https://finnhub.io/api/news?id=e8337372151f714ae01b0a5967c7e8b1413fdd0ab123816810f24b89b0eb1f0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is no longer trading like a stock that investors have simply overlooked. The shares closed at $264.74 on September 30, considerably up from $185.42 a year earlier, or around 41.66%. Over the same period, the S&P 500 gained about 14.41%. There are nine healthcare stocks other than JNJ in our ranking […]",
                "category": "company",
                "datetime": 1791723964,
                "headline": "Johnson & Johnson Stock Has Surged 44%, Can Its Growth Justify the Valuation?"
              },
              {
                "id": 142803294,
                "url": "https://finnhub.io/api/news?id=5e8f197db47b7b6d8bd38f3b4d9fa814ebd4707c80004e6fae294f092d1c515e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Earnings are back in session this week as the Big Banks open their books. We are also seeing the return of the telecom wars and a key inflation reading that may decide the Fed's next move.",
                "category": "company",
                "datetime": 1791712800,
                "headline": "Welcome back to earnings season: What to watch this week"
              },
              {
                "id": 142804559,
                "url": "https://finnhub.io/api/news?id=3d4fc2e376dab5b8cd33e165814050e7c200db7e30067e8f8149a1723ca39726",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364599252/image_1364599252.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Get ready for a market-moving week: CPI, big bank earnings, TSM and Tesla catalysts, plus a bullish energy outlook spotlighting Petrobras.",
                "category": "company",
                "datetime": 1791701872,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 142797825,
                "url": "https://finnhub.io/api/news?id=d0e4c844dfa87ed4f53dd4d26660626a03de6fc78fae246c12d12553264f870b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.",
                "category": "company",
                "datetime": 1791686100,
                "headline": "How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?"
              },
              {
                "id": 142790416,
                "url": "https://finnhub.io/api/news?id=06a7731bb4826c72095cad1c75f0333420ac83a0394b3d16b3be7911c41049b5",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "JNJ dividend analysis: 3.12% yield, 8/10 dividend rating, strong profitability, and moderate health support a durable payout for income investors.",
                "category": "company",
                "datetime": 1791634855,
                "headline": "Johnson & Johnson (NYSE:JNJ): Dividend Quality Makes It a Durable Income Pick"
              },
              {
                "id": 142792567,
                "url": "https://finnhub.io/api/news?id=11a786498782afaccf0262d5570d06ee18a18ddd114c981cf9f7594cc7351290",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Preview next week’s market-moving events—CPI, retail sales, Fed talk, and big bank earnings (JPM, GS, C, MS).",
                "category": "company",
                "datetime": 1791630000,
                "headline": "Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In Focus"
              },
              {
                "id": 142786629,
                "url": "https://finnhub.io/api/news?id=f66b0423a2a2b3fa6a5276bf2b8754aec04cf879a0e567a372fda1137e62cc17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A 50-year dividend grower and a monthly income REIT; how J&J and Realty Income build lasting wealth for patient investors.",
                "category": "company",
                "datetime": 1791625800,
                "headline": "2 Dividend Stocks Worth Holding Forever (Including 1 Dividend King)"
              },
              {
                "id": 142772223,
                "url": "https://finnhub.io/api/news?id=d7341b07311e0a7aadb936df0d126442fa321eed83f51e517867f131ac1fb044",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.",
                "category": "company",
                "datetime": 1791593224,
                "headline": "Why Is Everyone Ignoring Gilead Stock's High Cash Yield?"
              },
              {
                "id": 142767863,
                "url": "https://finnhub.io/api/news?id=73b59c6d79519f821571c067bc86a653580406c019b010d3e65a46f0a8aaa077",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Upcoming reports from the big banks next week will shift the Q3 earnings season into a higher gear, with a total of 29 S&P 500 members on the week's reporting docket. Estimates remain positive, with S&P 500 earnings expected to grow 24.3% YoY on 11.5% higher revenues.",
                "category": "company",
                "datetime": 1791585420,
                "headline": "Estimates Keep Rising as Q3 Earnings Season Takes Center Stage"
              },
              {
                "id": 142767120,
                "url": "https://finnhub.io/api/news?id=c8c71c37c6d03c767c8f78cc35c73b0966c71f17a01166df3fea665dc7f4fed3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Coca-Cola (NYSE:KO) and Johnson & Johnson (NYSE:JNJ), while operating in completely different industries, factored into the discussion in Cramer’s October 2nd morning appearance. The CNBC TV host discussed the two as stocks that could be bought on the back of weakness in the economy indicated through the jobs report, which saw the US add a […]",
                "category": "company",
                "datetime": 1791577305,
                "headline": "Coca-Cola (NYSE:KO) & Johnson & Johson (NYSE:JNJ): Buy Them For The Dividends, Says Jim Cramer"
              },
              {
                "id": 142765954,
                "url": "https://finnhub.io/api/news?id=e8e3b8da2da0d6ae4d9558e72857a3ca0885d2701f5b383c0d396564a0c319c7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Friday.",
                "category": "company",
                "datetime": 1791573008,
                "headline": "Friday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142766263,
                "url": "https://finnhub.io/api/news?id=8ec035baab86cf7792f8c473ed9d920f88a6b869215a9474bf070dbaea0125ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a year of drug approvals and clinical trial results, arriving just as the company prepares for the patent loss on Keytruda, its top-selling drug. So what did Merck show investors over those twelve months.",
                "category": "company",
                "datetime": 1791569538,
                "headline": "Does The Move In Merck Stock Change Anything?"
              },
              {
                "id": 142764645,
                "url": "https://finnhub.io/api/news?id=017ffc0a54b8f782db50580fa23a16d185b394840ad8991564195fa4ddb45199",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791564011,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 140542605,
                "url": "https://finnhub.io/api/news?id=216d128b83f71d76e6bce40b8b46e11723d78dea2fbe2da4a9c9e36d4bf5b412",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.",
                "category": "company",
                "datetime": 1791557801,
                "headline": "Earnings Calendar and Analysis for This Week (June 8-12)"
              },
              {
                "id": 142764048,
                "url": "https://finnhub.io/api/news?id=6003141fb7f092a9cb6581021fa7c4f6c814d640e9c7bbacebc3f104cc400856",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Boston is seeking an injunction and damages regarding alleged patent infringement relating to J&J subsidiary Atraverse's Hotwire system.",
                "category": "company",
                "datetime": 1791556345,
                "headline": "Boston sues J&J subsidiary over alleged patent infringement for cardiology device"
              },
              {
                "id": 142764050,
                "url": "https://finnhub.io/api/news?id=6241482d4670bb6f2d789158b7ebcd3d68f4b48589cd9e9642a3ae4bc086e46c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.",
                "category": "company",
                "datetime": 1791554580,
                "headline": "Cancer Stocks to Consider as Oncology Innovation Accelerates"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 249,
            "discarded_article_count": 225
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.3,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 7240250,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 8299650,
              "avg_vol_20": 7643465,
              "avg_vol_30": 7240250,
              "range_pct_10": 0.07182097349953204,
              "range_pct_20": 0.11232768253531943,
              "range_pct_30": 0.11232768253531943,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1463209143330686,
              "dist_to_20d_high": 0.027686007060058644,
              "down_shrink_days": 1,
              "breakout_level_20d": 275.23001,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.6393880108489661
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.586637367312035,
              "turnoverUsdM": 2599.7695025523,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.JNJ",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 253.7658,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 2.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 5.2,
            "take_profit_price": 284.4884,
            "target_multiplier": 1.9,
            "technical_strength": 1.93,
            "take_profit_percent": 6.3
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2177972992300024,
          "stopLossPercent": 5.17327473462407,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 6.9221,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.59
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 81.25
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0093
    },
    "kdj": {
      "d": 56.26,
      "j": 95.4,
      "k": 69.31,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 47.39
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -1004430,
      "recentSlope": -183833,
      "previousSlope": -2341570
    },
    "rsi": 59.66,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 245.7878,
      "position": "SAR喺價下",
      "distancePct": 8.15,
      "previousTrend": "上升"
    },
    "ma50": 265.1672,
    "macd": {
      "macd": -1.6907589234813827,
      "trend": "看漲",
      "signal": -2.6037756137836756,
      "histogram": 0.9130166903022929
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 258.2022,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 1
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.24,
      "score": 6,
      "avgVolume": 7813174,
      "currentVolume": 9714770
    },
    "derived": {
      "ma20": 259.394,
      "ma50": 265.1672,
      "prevClose": 257.78,
      "avgVolume10": 8653847,
      "avgVolume20": 7813174,
      "changePercent": 3.81,
      "avgVolumeForScore": 7813174
    },
    "ma_cross": {
      "ma20": 259.394,
      "ma50": 265.1672,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 259.5475,
      "prevMa50": 265.0322,
      "spreadPct": 2.18,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 246.7434,
      "upper": 272.0446,
      "position": "上半部"
    },
    "rsi_short": 81.63,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.24
    }
  }
}

{
  "close": 267.61,
  "volume": 9714770,
  "changePercent": 3.81
}